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1  
1. INTRODUCTION / STATE OF RESEARCH 
 
1.1. BASIS OF NEURONAL EXCITABILITY 
At the end of the 18th century Galvani and Volta suggested that propagation of nerve impulses 
and muscle contraction are based on electrical signals. In 1902, Bernstein hypothesized that in 
nerve and muscle cells the unequal distribution of potassium (K+)- ions over the cell 
membrane and the selective K+-permeability produces the resting potential and that a transient 
breakdown of selective permeability induces excitation, allowing other ions to pass the 
membrane. These changes in ion permeability along the axon of a neuron were suggested to 
build the backbone of the propagation of nerve impulses. Isolation of the squid giant axon and 
subsequent electrophysiological experiments by Hodgkin and Huxley in 1952 revealed that 
ion movements are the basis for the propagation of nerve impulses and local changes of the 
membrane potential (Zubay, 2000). 
In the central nervous system (CNS) communication between neurons is based on both 
electrical and chemical means. A prerequisite for propagation of electrical signals are gap 
junctions and a cytoplasmatic continuum between presynapse and postsynapse. A 
communication based on chemical means  (e.g. neurotransmitters or hormones) involves a 
ligand that travels the distance between the cell by diffusion and binds to specific proteins 
(Luddens and Korpi, 1995; Rang et al., 2003). 
 
1.2 γ-AMINOBUTYRIC ACID (GABA) 
GABA (see structural formula in Fig. 1) is the major inhibitory neurotransmitter in the CNS 
of the mammals (Sieghart, 1995; Barnard et al., 1998; Sieghart, 2006). GABA is synthesized 
from glutamate catalysed by two isoforms of the glutamic acid decarboxylase (GAD) GAD 65 
and GAD 67 (Erlander et al., 1991). GABA is stored in synaptic vesicles by vesicular 
neurotransmitter transporters and released from nerve terminals by calcium-dependent 
exocytosis (Owens and Kriegstein, 2002). There is also evidence for non-vesicular secretion 
of GABA by e.g. reverse transporter action, a mechanism that might be of particular relevance 
during brain development (Attwell et al., 1993; Taylor and Gordon-Weeks, 1991). GABA 
interacts with ionotropic GABA type A (GABAA) and metabotropic GABA type B (GABAB) 
receptors, which can be localized either pre- or postsynaptic (Bormann, 2000; Owens and 
Kriegstein, 2002). Reuptake of the neurotransmitter into nerve terminals and/or surrounding 
glial cells by the plasma-membrane bound GABA transporter (GAT) terminates the action of 
the neurotransmitter (Cherubini and Conti, 2001). GABA is finally metabolised by a 
2 
transamination reaction, which is catalysed by the GABA transaminase (GABA-T) (Owens 






Figure 1 Structural formula of GABA 
 
1.2.1 GABAERGIC NEURONS 
GABA is present in approximately 20-50% of all cerebral cortex synapses (Halasy and 
Somogyi, 1993; Bloom and Iversen, 1971; Hevers and Lüddens, 1998). In the neocortex, most 
of the GABA-containing neurons are apparently interneurons with few dendritic spines. They 
are classified as sparsely spiny, aspiny or smooth cells. These cells are further subdivided into 
groups such as basket cells, chandelier cells, double bouquet cells, local plexus neurons or 
neurogliaform cells. GABAergic neurons differ in respect to their morphology, neurochemical 
composition, somatic location and terminal arborization. GABA containing neurons are 
apparently distributed throughout the cortical lamina (Owens and Kriegstein, 2002). 
GABA interneurons are further classified in respect with their intrinsic membrane properties 
and synaptic connectivity (Connors and Gutnick, 1990; Gupta et al., 2000). Most GABA-
containing neurons in the neocortex are generated and migrate from subcortical rather than 
from cortical locations (Anderson et al., 1997). 
It has been proposed that in addition to the local circuit neurons, direct GABAergic afferents 
project to the cortex from the basal forebrain and the zona incerta (Owens and Kriegstein, 
2002). 
 
1.2.2 GABAERGIC SYNAPSES 
Neocortial synapses differ in their ultrastructure and are thus divided into 2 groups: type 1 and 
type 2 synapses (Gray, 1959; Owens and Kriegstein, 2002). Type 1 synapses are characterized 
by an asymmetrical membrane density at the synaptic cleft and are assumed to be excitatory, 
while type 2 synapses exhibit a symmetrical appearance and are considered to be inhibitory. 
There is evidence that more than 15% of all adult cortical synapses are inhibitory and thus, 
contain GABA.  
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GABAergic synapses are present in all neocortical layers, and in particular on cell somata, 












Figure 2 Schematic diagram of the synthesis and transport of GABA at synapses (Owens and 
Kriegstein, 2002) 
 
GABA mediates its effect by interacting with i.) GABAA receptors representing ligand gated 
chloride channels (Sieghart, 1995), ii.) G-Protein coupled GABAB receptors that modulate 
Ca2+- and K+- channels via G-proteins and iii.) GABAC receptors (Barnard et al., 1998; 
Bormann, 2000). However, this classification system is controversially discussed (see Barnard 
et al., 1998; Bormann, 2000). 
 
1.3 GABA TYPE A (GABAA) RECEPTORS 
GABAA receptors, the major inhibitory neurotransmitter receptors, belong to the superfamily 
of ligand-gated ion channels (LGICs) (Sieghart, 1995; Sieghart, 2006). This family comprises 
amongst others the nicotinic acetylcholine (nACh receptosr), serotonin subtype 3 (5-HT3 
receptors) or glycine receptors (Barnard et al., 1998; Minier and Sigel, 2004; Conolly and 
Wafford, 2004).  
Ligand-gated ion channels such as GABAA receptors are commonly formed by assembly of 5 
subunits (Conolly and Wafford, 2004, Sieghart, 2006). So far, nineteen different isoforms of 
mammalian GABAA receptor subunits have been cloned: α1–6, β1–3, γ1–3, δ, ε, pi, ρ1-3 and θ 


















Figure 3 Model structure of the extracellular domains of GABAA receptor extracellular domains 
showing the arrangement for α1, β2 and γ2 containing GABAA receptors (view from extracellular) 
(Ernst et al., 2003). 
 
The knowledge about the assembly of a certain subunit combination in neurons is limited and 
many different subunit combinations are expected to be present in the brain (McKernan and 
Whiting, 1996). There is evidence that the major receptor subtype of the GABAA receptor in 
adults comprises α1-, β2-, and γ2-subunits in a 2:2:1 stoichiometry (Chang et al., 1996, Tretter 
et al., 1997; Baumann et al., 2002, Sieghart and Sperk, 2002).  
The putative membrane topology of a single subunit is schematically represented in Fig. 4. 
Each subunit has an extracellular, β-rich, N-terminal domain of approximately 200 amino 
acids, which comprises ligand binding sites such as for GABA or benzodiazepines and the 
highly conserved Cys-loop. 2 β-sheets form a “sandwich” (Brejc et al. 2001) designated as 
“inner” and “outer” sheet (Unwin et al., 2002). The inner and outer sheet are connected by the 
signature disulfide bridge (Ernst et al., 2005).  The C-terminus is similar sized with 4 
hydrophobic membrane spanning domains (M1-M4) (Horenstein et al., 2001). The M1-M4 
segments are assumed to be α-helical (Ernst et al., 2005). Because both the N-terminus and C-
terminus of GABAA receptor subunits extend outside the cell membrane, the intracellular M3-
M4 loop becomes the most important domain interacting with the intracellular environment, 
e.g. providing protein-protein interactive domains involved in regulating synaptic localization 
and intracellular trafficking (Chen and Olsen, 2007). The chloride-conducting pore is flanked 


















       























Figure 5  
Illustration of the topology of a subunit of cys-loop 
receptors. The secondary structure motifs that are 
assumed be conserved are shown in ribbon 
representation, strand numbering is shown in Arabic 
numerals, whereas numbering of the membrane 
spanning helices is shown in Roman numerals. The 
important topologically conserved but structurally 
variable regions are indicated only schematically. The 
hydrogen bonds of the inner sheet are illustrated in light 
blue and outer sheets’ hydrogen bonds are depicted in 
red. All features associated with the plus side are 
depicted in orange, those belonging to the minus side 
are green. The cys-loop is shown in yellow, and the 
disulfide bond is shown as a yellow double arrow 




Another common feature of GABAA receptors is a highly conserved sequence in the M2 
region encompassing the amino acids TTVLTMTT (Korpi et al., 2002). 
Upon activation of GABAA receptors, the intrinsic chloride channel opens. Depending on the 
reversal potential of the permeating ions (chloride and bicarbonate) the postsynaptic GABA 
response can be either excitatory or inhibitory. Since the intracellular concentration of 
chloride in most mature neurons is low, the chloride reversal potential is negative to the action 
potential threshold. Activation of GABAA receptors exerts an inhibitory influence on the 
neuron (Akk et al., 2007). However, there is recent evidence that GABA-mediated responses 
can be also excitatory especially in immature neurons (Bernard et al., 1998; Ben-Ari, 2002). 
An inhibitory postsynaptic potential is triggered by the release of presynaptic GABA that 
binds to postsynaptic GABAA channels. IPSCs are characterized by a fast activating current 
with a rise time of approximately 1 millisecond or less that decays to the baseline over tens or 
hundreds of milliseconds (Macdonald et al., 2004). 
 
1.4 GABAA RECEPTOR DYNAMICS 
1.4.1 ASSEMBLY OF GABAA RECEPTORS 
Assembly of GABAA receptor subunits to functional receptors requires specific signaling 
sequences for the interaction of the subunits (Korpi et al., 2002). 
A glia-derived protein binding acetylcholine was identified in the molluscan CNS (Smit et al., 
2001). This protein exhibits a high degree of sequence similarity to the N-terminus of 
nicotinic acetylcholine receptor subunits including the domains that are assumed to form the 
agonist binding sites and a cysteine loop with 12 intervening amino acids (instead of 13 as 
reported for e.g GABAA receptors, see Ernst et al., 2005). It lacks, however, the membrane 
spanning domains and it forms soluble (i.e. non-membrane-bound), homopentameric 
complexes (Brejc et al., 2001). In analogy with the acetylcholine binding protein it is assumed 
that the extracellular N-terminus apparently represents a major determinant for the subunit 
assembly in ligand gated ion channels (Korpi et al., 2002). A 70 amino acid stretch in the 
second half of the N-terminal extracellular domain determines homooligomeric assembly of 
the GABAC receptor composed of ρ1 subunits (Enz and Cutting, 1999).  
Klausberger et al. (2001a) suggested that the regions α1(80- 100) and γ2(91–104) participate 
in subunit interaction, assembly and formation of the benzodiazepine binding site in 
recombinant α1β3γ2 receptors. An adjacent region of the γ2 subunit γ2(83–90) was suggested to 
mediate assembly with α1 and β3 subunits- (Klausberger et al., 2000).  
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Truncated N-terminal extracellular domains of GABAA receptor γ2 (1-234) and α1 subunit 
dimers can form a benzodiazepine binding site, while [3H]muscimol binding apparenly 
requires the presence of transmembrane domains of both α and β subunits (Klausberger et al., 
2001b). 
 
1.4.2 TARGETING AND REGULATION OF MEMBRANE  
         EXPRESSION 
De novo synthesis and assembly of GABAA receptor subunits occurs in the endoplasmatic 
reticulum. After correct assembly GABAA receptors are targeted to the plasma membrane via 
the Golgi apparatus where they might aggregate and anchor to subsynaptic elements to form 
synaptic clusters. Unassembled receptor subunits are degraded (Kneussel, 2002).  
A protein - GABAA receptor-associated protein (GABARAP)- involved in GABAA receptor 
plasma membrane targeting has been identified (Wang et al., 1999). GABARAP comprises 
117 amino acids and is expressed ubiquitously in all tissues including several areas of the 
CNS. The N-terminal domain of GABARAP (amino acids 1–36) is highly charged and 
features a tubulin binding motif that interacts with both soluble tubulin and polymerized 
microtubules, while the GABAA receptor γ2-subunit interacts with residues 36–68 (Wang et 
al., 1999; Kneussel, 2002). Residues 37–117 of GABARAP were shown to interact with the 
tubulin-binding protein gephyrin. Interestingly, this interaction with GABAA receptors is 
limited to γ1, γ2S, and γ2L, but does not occur with other GABAA receptor subunits (Wang et 
al., 1999; Nymann-Andersen et al., 2002; Chen and Olsen, 2007).  
Chen et al. (2000) suggested that co-expression of GABARAP and different GABAA receptor 
subunits leads to GABAA receptor aggregates that influence the function of surface GABAA 
receptors. This indicates an involvement of GABARAP in the organization of GABAergic 
synapses or alternatively a participation of GABARAP in membrane fusion events underlying 
organizational processes at GABAergic synapses (Kneussel, 2002). Postsynaptic receptors are 
likely to be saturated by presynaptically released transmitters. Thus, an increased number of 
active postsynaptic receptors represents an efficient way of strengthening synaptic efficacy. 
Processes facilitating the insertion of newly synthesized or recycled receptors into neuronal 
membranes to maintain a stable cell surface receptor number, therefore seem to be a critical 
requirement for the regulation of synaptic strength (Kneussel, 2002).  
The insulin receptor tyrosine kinase (Wan et al., 1997) and the ubiquitin-like protein Plic-1 
(Bedford et al., 2001) have been suggested to be involved in regulation of GABAA receptor 
surface expression (Kneussel, 2002). 
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Insulin causes a rapid translocation of GABAA receptors from the intracellular compartment 
to the plasma membrane in heterologous expression systems. This process has been shown to 
be specifically dependent on the presence of a GABAA receptor β2-subunit (Kneussel, 2002). 
In neurons, the expression of GABAA receptors on dendritic and postsynaptic membranes is 
also enhanced by insulin suggesting that a rapid recruitment of functional receptors is 
regulated via pathways that include the activation of growth factor receptors (Kneussel, 
2002). 
However, the receptor density on the membrane is also regulated by negative modulators of 
the protein degradation machinery at the proteasome. In proteasomes, poly-ubiquitinated 
substrates are unfolded and degraded to small peptides. In humans, the proteins Plic-1 and 
Plic-2 represent apparently ubiquitin-like proteins that physically interfere with both 
proteasomes and ubiquitin-ligases. Thus, overexpression of Plic proteins interferes with the in 
vivo degradation of ubiquitin-dependent proteasome substrates. Plic-1 has been further shown 
to bind to both α and β subunits of GABAA receptors leading to an increased number of 
receptors available for insertion into the plasma membrane. Further support for this scenario 
comes from the finding that a blockade of the interaction of Plic-1 with GABAA receptors 
results in a time-dependent reduction in whole-cell GABA-activated current amplitudes.  
Thus, Plic-1 is probably involved in controlling GABAA receptors subunit half-life (Kneussel, 
2002). In contrast, the neurotrophic factor BDNF (Brain-derived neurotrophic) factor has been 
suggested to negatively modulate GABAA receptor surface expression (Brunig et al., 2001). A 
close connection between GABAA receptor down-regulation and voltage-gated calcium 
channels has been proposed (Lyons et al., 2001), which is supported by the finding that 
nifedipine inhibits both GABA-induced increases in calcium concentrations and GABAA 
receptor downregulation. Taken together, the surface expression of GABAA receptors is a 
regulated by processes including positive and negative modulatory pathways (Kneussel, 
2002). 
 
1.4.3 CLUSTERING OF GABAA RECEPTORS AT SYNAPSES 
Gephyrin was initially described as 93 kDa protein that was co-purified with glycine receptors 
(Pfeiffer et al., 1982). Gephyrin, however, shows a wider expression over the CNS as well as 
in peripheral tissues (Prior et al., 1992). Gephyrin is a multifunctional protein accounting for 
both molybdenum cofactor synthesis and the clustering of glycine and GABAA receptors at 
inhibitory synapses. 
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The underlying mechanism of clustering at the synapse, however, is complex and currently 
not well understood. Removal of gephyrin by gene targeting or mRNA expression 
interference strongly affects GABAA receptor clustering (Fritschy et al., 2008). 
Mice lacking gephyrin die after birth and exhibit reduced clustering of glycine receptors at 
their synapses (Feng et al., 1998) and a reduction in GABAA receptor α2 and γ2 subunits in the 
spinal cord (Kneussel et al., 1999). In primary hippocampal neuronal cultures, diminished 
synaptically clustered GABAA receptors have been detected, while the intracellular pool of 
GABAA receptors was increased (Korpi et al., 2002). In analogy to the gephyrin-knockout 
mice, γ2- knockout mice show also decreased GABAA receptor clustering (Craig et al., 1996; 
Essrich et al., 1998), providing evidence for a dominant role for gephyrin and γ-subunits in 
GABAA receptor clustering. As for GABARAP, the gephyrin interaction with GABAA 
receptors is limited to γ1, γ2S, and γ2L, (Wang et al., 1999; Nymann-Andersen et al., 2002; 

































1.4.4 GABAA RECEPTOR INTERNALIZATION AND RECYCLING 
The uptake (endocytosis) of extracellular material and membrane proteins into cells via 
membrane-bound vesicles is mediated by proteins that cycle between the synaptic membrane 
and intracellular sites (Liang and Huganir, 2001; Marsh and McMahon; 1999; Noel et al., 
1999; Kneussel, 2002). There is evidence that GABAA receptors are internalized from cell 
bodies and dendrites via clathrin-mediated endocytosis (Kittler et al., 2001; Korpi et al., 
2002).  
This process (interaction of the adaptin complex AP2 with the GABAA receptor β and γ 
subunits) has been shown to be critical for the recruitment of integral membrane proteins into 
clathrin-coated pits. Blocking the clathrin-dependent endocytosis results in large, sustained 
increases in the amplitude of miniature IPSCs in cultured neurons suggesting a constant cycle 
of GABAA receptors between synaptic sites and endocytic structures (Kneussel, 2002). 
 
 
1.5 STRUCTURAL DETERMINANTS OF THE AGONIST BINDING SITE 
Nicotinic ACh receptor models have strongly influenced the design of structural models for 
the family of ligand-gated ion channels. The agonist binding site is formed by 6 loops 
designated A through F (Corringer et al., 2000; Sedelnikova et al., 2005).  
GABA binding is assumed to occur at the interface α/β (see Figure 6), whereas 













In analogy to the agonist binding site of nACh receptors (see Corringer et al., 2000), the 
GABA binding site at the α/β interface is predicted to be constituted by 6 loops designated A-
 
Figure 7 
Side view of the GABA binding site at 
the α/β subunit interface. The putative 
GABA-binding region is depicted in 





F with several residues of these loops facing the binding site (Boileau et al., 2002a; Ernst et 
al., 2003; Ernst et al., 2005). α1 contributes to the loops D and E, whereas loops A, B, C and F 
are formed by the principal binding site of β2. Loop A defines approximately the region 
β2Trp92-Asp101. This region is assumed to be a β-strand. Leu 99 and Tyr 97 have been 
identified to line the GABA binding site (Boileau et al., 2002a). Loop B comprises the region 
β2Ile154-Asp163. Loop B is formed by β-strand 9, loop 10 and the beginning of β-strand 10. 
β2Thr160 and β2 Asp163 are assumed to line the GABA binding site. Interestingly, mutation 
E155C produces spontanousely open channels by altering both channel gating and agonist 
binding (Newell et al., 2004). Loop C is formed by the region β2 V199-S209, residues S204, 
Y205, R207 and S209 have been shown to face the agonist binding site. In contrast, F200, 
S201, T202 and G203 do not directly face the binding site, but if mutated they drastically 
affect the sensitivity to GABA. Loop C has an extended conformation that may traverse the 
GABA binding site from its rim to its depth. This region, which does not show a regular 
secondary structure, is assumed to represent an extended coil or loop (Wagner and 
Czajkowski, 2001). After agonist binding loop C is predicted to move inward towards loop E 
(Unwin et al., 2002; Celie et al., 2004, Law et al., 2005). 
The region of α1Y59 to K70 comprises loop D. Residues F64, R66 and S68 are major 
determinants of GABA binding. This region is likely to be constituted by a β-strand (Boileau 
et al. 1999). Loop E is formed by the region α1Met113-Leu132 and linked to loop A of the 
benzodiazepine binding site via an 11 amino acid stretch. In this region Asn 115, Leu 117, 
The 129 and Arg 131 are assumed to line the agonist binding site (Kloda and Czajkowski, 
2007). 
Loop F - formed by the region α1Pro174-Asp191- is poorly conserved in GABAA- receptor 
subunits. Residues V178, V180, D183 are assumed to contribute to the GABA binding site. 
Loop F is predicted to be a random coil (Newell and Czajkowski, 2003) 
 
1.6 GATING OF GABAA RECEPTORS 
The binding of a neurotransmitter to its binding site is assumed to result in the opening of the 
ion channel within the transmembrane domain, a process known as activation or ‘gating’. It 
has been suggested that neurotransmitter binding to the agonist binding site results in a local 
perturbation of its structure (Grosman & Auerbach, 2001; Dahan et al., 2004; Beene et al., 
2004). This structural change is further propagated along the longitudinal axis of the receptor 
through the extracellular domain as a ‘wave’ of conformational changes (Grosman et al., 
12 
2000), Finally, a physical gate is moved within the membrane spanning domain, resulting in 
an ion flux through the pore (Keramidas et al., 2006). 
 
“pin-into-socket mechanism” 
 For the nicotinic ACh receptor, the copuling of the the extracellular domain with the 
membrane domains has been suggested to be a “pin-into-socket” mechanism based on the 
structure published by Miyazawa et al. (2003). It was proposed that a single valine residue in 
the extracellular domain (V261) enables contact with the transmembrane domains serving as a 
pivot, permitting a rotation of the extracellular domain induced by agonist binding to be 
transduced to the M2 segments. The resulting rotation of the M2 segments enables thus the 
pore to expand at its narrowest point (Kash et al., 2004a).  
“conformational-wave-mechanism” 
Binding of the agonist to its binding site was also alternatively suggested to initiate a series of 
local movements that are transduced to the membrane spanning domains (Kash et al., 2004a) 
In such a scenario, the extracellular N-terminal domain of the GABAA receptor connected to 
the M1 domain and thereby interacts with the loop between M2 and M3 (M2-M3 linker). In 
analogy to a model for the AchBP, it has been suggested that loops 2 and 7 of the GABAA 
receptor α subunit interact with a lysine residue in the M2-M3 linker to couple GABA 
binding to gating (Kash et al., 2003). Moreover, it was proposed that gating induced a 
conformational change in and/or around the N-terminal half of the M2-M3 linker (Bera et al., 
2002). For gating of the ACh receptor it was suggested that the loop 2 of both α subunits is in 
direct contact with the distal M2 regions (just before the beginning of the M2-M3 linker). 
Upon acetylcholine binding both loops rotate by 15° around an axis passing through the 
disulfide bridge. The rotations of the loops are associated with rotations of the M2 domain, 
which are translated to the gate and might presumably result in the opening of the gate 
(Unwin et al., 2002; Miyazawa et al., 2003). It was further suggested that the α1K220 residue 
plays an active role in the transduction process that converts the energy associated with the 
binding of agonist to the opening of the ion pore. The β-10 strand (pre-M1 segment) appears 
to be an integral component of a ‘coupling zone’ that includes loops 2 and 7 and the M2–M3 
linker (Keramidas et al., 2006). 
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1.7 STRUCTURE OF THE ION PERMEATION PATHWAY 
The structural basis of ion permeation and selectivity was intensively investigated by Xu and 
Akabas, 1993; Xu and Akabas, 1996 and Goren et al., 2004. Residues assumed to line the 











Moreover, the hydroxylgroups on the side chains are assumed to interact with the water 
molecules that form the hydration shell surrounding the chloride ions thereby providing 
energetic stabilization for ions when they enter the pore domain, as previously shown for K+ 
channels (Roux and MacKinnon, 1999; Kash et al., 2004a). This mechanism can be applied to 
both positively and negatively charged ions. A similar hydrophilic sequence (TMTT) was 
identified in many K+- channels. In K+- channels the threonine residues have been shown to 
comprise the walls of a large water-filled cavity in the center of the channel, deep within the 
membrane (Doyle et al., 1998; Kash et al., 2004a). Thus, it has been assumed that this 
hydrophilic region of M2 is presumably not involved in ion selectivity for GABAA receptors, 
but it might enhance the channel conductance (Kash et al., 2004a). 
 
1.8 STRUCTURE OF THE SELECTIVITY FILTER 
By comparison of the permeability of several inorganic and organic anions, it was suggested 
that the selectivity filter (narrowest portion of the pore) of GABAA receptors is 5.6 Å wide 
(Bormann et al., 1987). Several conserved positively charged residues (arginine and lysine) 
are clustered around the extracellular end of the M1 and M2 segments. It was suggested that 
they might play a role in charge selectivity by concentrating negative ions within the channel 
 
Analysis of the sequence of the M2 segments of 
different GABAA receptor subunits reveals a high 
degree of sequence identity, including several highly 
or absolutely conserved hydrophilic residues, such as 
threonine residues at positions 7’, 10’ and 13’, that can 
be found in all of the GABAA receptor subunits, while 
other positions may feature either a serine or threonine 
(Kash et al., 2004a). 
 
Figure 8 Schematic illustration of the M2 region of α1 and β2 subunits, showing the residues 
contributing to the pore. Residues that can preferentially interact with water molecules are depicted in 
blue (Kash et al., 2004a). 
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vestibule (Kash et al., 2004a). Xu and Akabas (1996) suggested that the selectivity filter 
might be located at two-thirds of the way down the M2 helix.  
There is recent evidence, that the M1–M2 loop of the β subunit plays a pivotal role in 
determining the ion selectivity of GABAA receptors (Jensen et al., 2002; Kash et al., 2004a). 
 
1.9 THE GATES 
The structure of the resting and desensitized channel gates in the resting or desensitized state 
in the presence of an agonist, is yet unknown (Kash et al., 2004a). There is evidence, that in 
some ion channels e.g. in the ClC chloride channel, the selectivity filter simultaneously 
represents the gate (Furst et al., 2000; Kash et al., 2004a). For K+- channels it has been shown 
that gate and selectivity filter are distinct structures located several Å apart (Kash et al., 
2004a). 
Five 9’ leucine residues that are apparently located in the center of the channel-lining M2 
segments making a symmetrical contribution have been assumed to form the resting gate of 
nACh receptors (Unwin, 1995; Brejc et al., 2001). However, there is recent evidence that both 
the resting gate and the selectivity filter of the nACh receptor are located in the M1-M2 loop 
(Wilson and Karlin, 1998; Wilson and Karlin, 2001; Kash et al., 2004a). 
For GABAA receptors it was suggested that the top of the channel gate is located in proximity 
to αV257, which would be approximately two helical turns more cytoplasmatic than the 
assumed 9´ leucine (Xu and Akabas, 1996; Kash et al., 2004a). Making use of substituted 
admantane derivatives non-competitive antagonism of different positions within the channel 
pore of nACh receptors was probed, providing further evidence for the suggestion of the 
location of the closed gate (Arias et al., 2002; Kash et al., 2004a). More evidence comes from 
trapping experiments with the open channel blocker picrotoxin inferring that the closed 
channel gate is located between the picrotoxin binding site (α1V257) and the channel’s 
extracellular end (Bali and Akabas, 2007) 
The structure of the desensitized gate of GABAA receptors is not known, although it is 
assumed to be distinct from the resting gate (Scheller and Forman, 2002). 
Based on the asymmetric structure of the selectivity filter, both the resting gate and the 
desensitization gate could represent an asymmetrically “collapsed” or constricted pore as 
shown e.g. for the selectivity filter of KcsA K+- channel in the presence of low K+ 




1.10 DISTRIBUTION PATTERN OF GABAA RECEPTOR SUBUNITS 
So far, 19 different subunits of mammalian GABAA-receptors have been identified; their 
expression pattern is heterogeneous. The α1 subunit represents the most widely expressed 
subunit among all α-variants. Except in the striatum, the reticular thalamic nucleus and the 
internal granular layer of the olfactory bulb α1 subunits are found in all parts of the brain. 
Receptors containing α2 subunits in contrast are found especially in the accessory olfactory 
bulb, dentate molecular layer, in the hippocampal area CA3, central and lateral amygdaloid 
nuclei, septum, striatum, accumbens and the hypothalamus. In the olfactory bulb (external 
plexiform and glomerular layers), the inner layers of the cerebral cortex, the endopiriform 
nucleus, the amygdala, the lateral septum, the claustrum and the superior colliculus α3 
represents the predominantly expressed α-isoform (Pirker et al., 2000). α5 subunits are 
expressed in high density in the external plexiform layer of the olfactory bulb, the 
endopiriform nucleus and the inner layers of the cerebral cortex. Additionally, α3- expression 
was found in the internal granular layer of the olfactory bulb (together with α2), the 
subiculum, the Ammon’s Horn and in ventromedial hypothalamic nuclei. Furthermore α5 was 
detected in the superior colliculus, ventral nuclei of the lateral lemniscus and nuclei of the 
trapezoid body (Pirker et al., 2000). The diazepam-insensitive α-variants, α4 and α6, are 
predominantly expressed in the thalamus (not including the ventral lateral geniculate, reticular 
and central medial nuclei), the striatum and nucleus accumbens, the tuberculum olfactorium 
and the molecular layer of the dentate gyrus (α4-isoform). α4 subunits were also detected, 
even though less dominantly distributed, in the cerebral cortex (mainly outer layers), the 
hippocampus (CA1), the septum, the colliculus superior (outer layers) and the brainstem. 
In granule cells of the cerebellum and the granular layer of the cochlear nuclei especially α6-
comprising GABAA-receptors are expressed. Expression of α6 in the olfactory bulb and the 
superior colliculus is still controversially discussed (Pirker et al., 2000). 
In contrast to the different α- subunits the β-variants are broadly distributed, in particular in 
the cerebral cortex. In some areas (mainly subcortical areas and the cerebellum), however, 
their distribution is complementary. As can be exemplified with high density of β2- containing 
receptors in the pallidum and a lower density in the striatum, whereas β3 represents the main 
β-variant in the striatum and is found in low concentrations in the pallidum. Strong staining 
for β1 is found in the CA2 subfield of the hippocampus. β2 represents the main β variant in the 
thalamic nuclei (with exception of the reticular nuclei), moreover it can be found in many 
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interneurons throughout the brain as well as in the cerebellum (together with β2). In the 
hippocampus β3 is incorporated in most GABAA receptors (Pirker et al., 2000). 
γ2 represents the predominantly expressed γ- variant. High density of γ2 was found over the 
CNS with exception of the thalamus (olfactory bulb, cortex, hippocampus, amygdala, septum 
and basal forebrain, pallidum, hypothalamus). In contrast, γ1 subunits shows a very limited 
distribution pattern. γ1 was detected in the pallidum, substantia nigra, septum, medial and 
central amygdaloid nuclei and in the bed nucleus of the stria terminalis. Weak expression of γ3 
mRNA was shown all over the CNS, stronger expression has been reported in cerebral cortex 
and the medial geniculate nucleus. There is also evidence for γ3 in the parabrachial nucleus.  
δ subunits comprising GABAA channels are mainly located in the cerebrellar granule cells, 
the thalamus, the dentate molecular layer and subiculum, cortex and striatum (Pirker et al., 
2000; Korpi et al., 2002). 
 
2.  MODULATION OF GABAA RECEPTORS 
2.1 BENZODIAZEPINES 
Since their introduction in clinics, benzodiazepines (BZs) belong to the most frequently 
prescribed drugs due to their sedative and anxiolytic properties in the treatment of anxiety 
disorders, insomnia, muscle spasms and epilepsy (Bateson, 2004; Savic et al., 2008). 
Benzodiazepines with a short plasma half-live (such as triazolam) are usually administered for 
the treatment of sleep disorders in order to avoid next day “hangover” effects. 
Benzodiazepines prescribed for the treatment of anxiety disorders such as clonazepam or 
lorazepam, however, display a longer half-live (Bateson, 2004).  
The use of benzodiazepines, however, is also associated with a number of unwanted side 
effects such as ataxia, daytime sedation, loss of coordination and impairment of memory and 
cognition (Kales et al., 1986; Kales et al., 1987). There is evidence that long-term 
administration of benzodiazepines is associated with the development of tolerance and an 
increased risk of physical and psychological dependence. After sudden cessation of 
benzodiazepine administration withdrawal symptoms are observed (Bateson, 2004). The 
underlying mechanism is still unknown. A simple down-regulation of the total GABAA 
receptor number does apparently not occur (Bateson, 2002). 
Until the discovery of a high-affinity binding site for benzodiazepines on GABAA receptors, 
the molecular target for benzodiazepines remained elusive (Mohler and Okada, 1977; 
Braestrup and Squirres, 1977; Sigel and Buhr, 1997). Drugs not comprising the classical 
benzodiazepine structure such as β-carbolines, imidazopyridines, triazolopyridazines or 
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cyclopyrrolones have been shown to interact with the putative benzodiazepine binding site 
(Sieghart, 1995). 
At synapses, GABAA receptors are activated by a rapid exposure to high concentrations of 
GABA. Benzodiazepines apparently prolong the decay of spontaneous miniature postsynaptic 
currents (mIPSC). It was shown that the amplitude of the mIPSCs is enhanced by 
benzodiazepines in different neuronal systems (Hajos et al., 2000) suggesting that the 
benzodiazepine-induced increased GABA affinity results in recruitment of additional GABAA 
receptors (Mohler et al., 2001). 
It is assumed that the enhancement of inhibitory GABAergic neurotransmission induced by 
benzodiazepines is based on the prolonged decay of the mIPSC. The increase of mIPSC 
amplitude is probably not based on an enhancement of the mIPSC peak amplitude, but more 
likely reflects the summation of several mIPSCs due to the drug-induced prolongation of the 
current (Mody et al., 1994; Mohler et al., 2001). 
 


















Figure 9 Illustration of the putative benzodiazepine binding pocket. Side view of the α and γ subunits, 




The α1 subunit containing residue α1H101 has been identified as the main subunit 
photoaffinity labelled by [3H] flunitrazepam (Duncalfe et al., 1996).  Additionally, a γ2 
subunit is a prerequisite for GABAA receptor modulation by benzodiazepines (Sigel et al., 
1990; Sigel and Buhr, 1997).  
In multiple binding studies several amino acid residues have been shown to influence 
benzodiazepine binding: Mutation of α3E225G (glycine is the homologous residue in the α1 
subunit) increased the affinity for zolpidem and Cl218872 (Pritchett and Seeburg, 1991). 
Substitution of H101 by arginine in the α1 subunit (α1H101R) resulted in a complete loss of 
diazepam, zolpidem and Cl218872 binding, whereas the binding affinity of [3H]Ro 15-4513  
was not affected (Wieland et al., 1992).  
Mutations α6R100H, α6P161T, α6E199G and α6I210V (mutation to the corresponding 
residues in the α1 subunit) drastically changed the affinities of benzodiazepine ligands 
(Wieland and Luddens, 1994). Mutation α1Y159S induced a complete loss of [3H]flumazenil 
binding (Amin et al., 1997). After mutating Tyrosine 209 in the α1 to glutamine (α1Y209Q) 
binding of [3H]flumazenil and [3H]flunitrazepam was abolished, while [3H]muscimol binding 
was not affected (Buhr et al., 1997c). In contrast, mutation α1T206A increases the 
enhancement of IGABA by diazepam and zolpidem (Buhr et al., 1996). 
Two amino acids in the γ2 subunit (γ2F77 and γ2M130) confer benzodiazepine sensitivity 
(Buhr and Sigel, 1997; Buhr et al., 1997a,b; Wingrove et al., 1997). Mutation γ2F77I leads to 
a complete loss of zolpidem, Cl218872 and DMCM binding, whereas high-affinity 
flunitrazepam binding was not affected (Wingrove et al., 1997). 
γ2F77Y apparently increased the affinity for zolpidem and Cl218872 (Buhr et al., 1997b). 
Substitution of γ2M130 by leucine results in drastically reduced zolpidem binding (Buhr and 
Sigel, 1997).  I77 and L130 in γ1 subunits correspond apparently to F77 and M130 in γ2 
subunits (Wingrove et al., 1997). 
The ligand-binding sites of neurotransmitter receptors such as nicotinic ACh, glycine and 
GABAA receptors are apparently formed by homologous amino acid loops located at the 
subunit interfaces (Galzi and Changeux, 1995). There is evidence that the GABA binding site 
and the benzodiazepine binding pocket are homologous. Moreover, not only homologous 
amino acid loops, but also multiple homologous amino acids are involved in both GABA and 
benzodiazepine binding. γ2F77/α64, α159/β157, α206/β202 and α209/β205 are apparently 
directly homologous to each other, while α200, α211 and γ130 are assumed to be located in 
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homologous regions to β205 and α120. It has therefore been suggested that many of the 
amino acid residues in the benzodiazepine binding site are directly homologous to amino 
acids in the GABA binding site. In analogy to GABA binding that is assumed to occur at α/β 
subunit interface, the benzodiazepine binding pocket is also assumed to be located at a subunit 
interface. Interestingly, no homologous amino acid for α1H101 has been identified in the 
GABA binding site (Sigel and Buhr, 1997). 
Additional amino acids determining benzodiazepine binding affinity include αY159, αY161, 
αT206, αY209, amino acid residues that are located in different regions of the GABAA 
protein, which have been suggested to be located close to each other. It has been proposed 
that both the α- subunit and the γ-subunit fold back after 50 amino acid residues. The correct 
three-dimensional arrangement of the benzodiazepine pocket remains to be established. It has 
been suggested that the region 199-209 of the α-subunit represents a α-helix (Sigel and Buhr, 
1997). α1G200, γ2A79 and γ2T81 have been suggested to form part of the benzodiazepine 
binding pocket (Berezhnoy et al., 2003). The region comprising residues γ2F77, γ2A79 and 
γ2T81 is assumed to form a β-strand and to undergo a conformational change during the 
gating process. Flurazepam is in direct contact with γ2F77 and it might occupy space within 
the binding site that is close to γ2A79 (Teissère and Czajkowski, 2001). Although a direct 
interaction of flurazepam with the alanine residue is unlikely, the small size of alanine might 
be crucial for providing space for benzodiazepines of different size. Berezhnoy et al. (2003) 
suggested that γ2A79 is most probably located in the access pathway of the benzodiazepine 
ligand to the binding pocket. Moreover, residue γ2D75 was suggested to play an important 
role in maintaining the architecture of the benzodiazepine binding pocket (Teissère and 
Czajkowski, 2001). 
An interaction of the 5’-phenyl substituent of classical benzodiazepines with γ2F77 via pi-pi 
stacking was hypothesized by Buhr et al., 1997b and Sigel et al., 1998. Amino acid residue 
α1H101 seems to be involved (McKernan et al., 1998; Davies and Dunn, 1998) as α1H101C 
covalently interacts with a reactive group attached to the carbon atom in diazepam that 
normally carries a chloride atom (Berezhnoy et al., 2003). 
 
2.1.2 BENZODIAZEPINE MECHANISM OF ACTION 
Binding of benzodiazepines is only the first step in enhancing IGABA (for review, see 
Colquhoun, 1998). The second step is a conformational change (Boileau and Czajkowski, 
1999) coupling benzodiazepine binding to an increased open frequency of GABAA channels 
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(Rogers et al., 1994). In contrast to barbiturates or neuroactive steroids benzodiazepines 
enhance GABA binding and increase the frequency of GABA-gated channel opening 
(Macdonald and Twyman, 1992; Vicini et al., 1987). They do, however, neither directly gate 
the receptor nor they alter the mean open time of the channel (Vicini et al., 1987; Campo-
Soria et al., 2006). 
Although binding occurs at the N-terminus, there are multiple domains of the receptor 
involved in transducing binding to an enhancement of GABAA receptor current (Jones-Davies 
et al., 2005). The classical concept of benzodiazepine enhancement of IGABA is explained by 
an increase of the apparent affinity of the GABA binding site for the agonist (Campo-Soria et 
al., 2006). From single channel studies there is evidence, that diazepam increases the rate at 
which monoliganded receptors open, although actually two GABA molecules are required for 
channel opening (Twyman et al., 1989; Rogers et al., 1994). It has been suggested that 
binding of benzodiazepines to the interface of α and γ2 subunits induces a conformational 
change that shortens the distance between the two subunits therefore transducing binding to 
allosteric modulation of GABAA receptors (Teissère and Czajkowski, 2001). Campo-Soria et 
al. (2006) suggested that benzodiazepine binding destabilizes the closed state of the receptor 
and benzodiazepines might act as very weak partial agonists for the GABAA receptor. 
Making use of chimeras (γ2-δ) and site-directed mutagenesis a crucial role of the distal portion 
of the M1 region, the distal portion of the M2 region and the M2-3 linker in coupling was 
identified. The pre-M1 region plays apparently a crucial role in transducing binding to gating. 
This hypothesis is based on the assmption that the pre-M1 region physically connects both the 
N-terminus (harbouring the putative binding site) and the M2-region (Jones-Davis et al., 
2005). 
Further support for such a scenario comes from a GABAA receptor model by Trudell and 
Bertaccini  (2004) indicating that the N-terminal region of the M1 before the conserved P243 
lines the receptor pore by intercalating between M2 channel-lining domains. Three residues 
γ2Y235, γ2F236 and γ2T281 have been identified in this region to be crucial for transduction 
(Jones-Davis et al., 2005). Residues γ2I282 and γ2T281 in the M2-M3 linker region - that are 
also involved in formation of an anaesthetic binding site (Jenkins et al., 2001)- have been 
shown to participate in “benzodiazepine transduction”, suggesting a scenario where the 
physically adjacent and intercalated extracellular M1 and M2 domains of the receptor act in 
concert to enhance GABAA receptor gating (Jones-Davis et al., 2005). 
It has been proposed that diazepam induces a conformational change of GABAA receptors that 
is structurally distinct from the closed, open, GABA-bound or desensitised states (Williams 
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and Akabas, 2000). However, Bianchi and Macdonald (2001) reported an enhancement of 
spontaneous GABAA receptor currents by benzodiazepines, a finding that does not agree with 
the classical mechanism of benzodiazepine action by enhancing microscopic affinity of the 
GABA binding site. 
The latter concept suggests that benzodiazepines facilitate gating by a mechanism similar to 
that of GABA. An analogy between gating models of ACh receptors (Unwin et al., 2002) and 
GABAA receptors (Kash et al., 2003) suggests that GABA binding to the interface of α and β 
subunits initiates a conformational change in the N-terminal region of the β-subunit. This 
conformational change results in a rotational opening of the girdle of the pore via the M2-M3 
linker- a process that requires a certain amount of energy. Structurally, these domains are 
localized in a manner to promote communication between these domains, as the N-terminal 
loop 7 is localized in parallel to the M2-M3 linker. Both loops have been shown to be flexible. 
On agonist binding the N-terminus undergoes a constriction resulting in a movement of the 
M2-M3 loop to the loop 7 of the N-terminus (Kash et al., 2003; Jones-Davies et al., 2005). 
Benzodiazepine binding at the α/γ interface might use an analogous pin-into-socket 
mechanism, which couples the N-terminal binding pocket (pin) through the M2 and the 
proximal portion of the M2-M3 loop (socket) (Jones-Davies et al., 2005). 
Transduction via the γ2 subunit might reduce the energy required for activation of GABAA 
receptor agonist binding sites by supplying a certain amount of energy of its own, that is, 
however, not sufficient to induce an opening of the channel. Jones-Davies et al. (2005) 
assumed, that benzodiazepines affect GABAA receptors by lowering the energy barrier that is 
required for GABA-mediated gating. 
Benzodiazepines produce a biphasic enhancement of α1β2γ2L receptors. The first component 
in the nanomolar concentration range is dependent on the presence of a γ-subunit and 
sensitive to antagonism by flumazenil. The low affinity component is mediated via α1β2 
receptors that are sensitive to benzodiazepines at micromolar concentrations. Two residues in 
the M2 and M3 region have been identified to confer sensitivity to the micromolar component 
of potentiation without affecting the nanomolar component (Walters et al., 2000). 
 
2.1.3 EFFECTS OF BENZODIAZEPINES ARE MEDIATED BY DIFFERENT     
          GABAA RECEPTOR SUBTYPES 
The relevance of GABAA receptor subtypes in mediating the different effects of 
benzodiazepines was established based on a gene knock-in strategy. Mice carrying mutations 
in the benzodiazepine binding pocket (point mutations α1H101R, α2H101R, α3H1261R or 
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α5H105R render the receptor insensitive to benzodiazepine modulation) were generated. 
These mice were expected to fail to display some effects of benzodiazepines and thus, the 
contribution of a certain subtype to a certain effect of benzodiazepines could be deduced 
(Rudolph et al., 1999; Rudolph et al., 2001; Mohler et al., 2002). 
 
 
2.1.3.1 GABAA RECEPTORS MEDIATING SEDATIVE-HYPNOTIC  
                            EFFECTS 
Sedative and hypnotic effects by benzodiazepines are mediated by GABAA receptors 
containing α1 subunits. This was demonstrated by the lack of motor activity depressing by 
diazepam and zolpidem action in the α1H101R mouse line (Rudolph et al., 1999; Crestani et 
al., 2000). This finding is supported by McKernan et al. (2000) with α1-subunit-selective 
benzodiazepine binding site ligands. 
Sedative effects of anaesthetics such as etomidate are also likely to be mediated by β2 subunit 
containing receptors. A similar approach was chosen (rendering the β3 subunit insensitive to 
modulation of etomidate by the mutation β3N265M). It was shown that mutant mice 
recovered their motor abilities quicker than wild type mice after i.p. application of etomidate 
(Reynolds et al., 2003).  
 
2.1.3.2 GABAA RECEPTORS MEDIATING AMNESIA 
Anterograde amnesia is one of the typically reported side effects of benzodiazepine treatment. 
The impairment of memory by diazepam is related to α1 containing receptors (Rudolph et al., 
1999; Mohler et al., 2001) 
 
2.1.3.3 GABAA RECEPTORS MEDIATING ANTICONVULSANT EFFECTS  
             OF BENZODIAZEPINES 
The anticonvulsant effect of diazepam is markedly decreased in the α1H101R mouse line. 
There is evidence that other than α1 containing GABAA receptors are involved in mediating 
the anticonvulsant effects, as the residual activity in α1H101R mice could be reversed by 
flumazenil. Thus, GABAA receptors containing α1 subunits are assumed to mediate partially 





2.1.3.4 GABAA RECEPTORS MEDIATING ANXIOLYTIC EFFECTS OF  
                            BENZODIAZEPINES  
There is evidence that anxiolysis after benzodiazepine treatment results from modulation of a 
population of neurons expressing GABAA receptors containing α2 subunits, as the α2 mutated 
mouse line is resistant to the anxiolytic effects of benzodiazepines. It was therefore suggested 
that ligands selectively interacting with α2-containing GABAA receptors represent promising 
leads for future anxiolytic drugs (Low et al., 2000). Moreover, the majority of GABAA 
receptors expressed in the amygdala, an area associated with strong impact on anxiety and 
fear, contain α2 subunits (LeDoux, 2000; Pirker et al., 2000). However, there is growing 
evidence, that drugs specifically modulating α3 containing receptors also exert anxiolytic 
effects (McKernan et al., 2000). It has been thus suggested that both α2 and α3 containing 
receptors contribute to the anxiolytic effects of benzodiazepines (Atack et al., 2006). The 
α2H101R mice failed, however, to display the anxiolytic effects of diazepam. It was 
suggested that higher doses of diazepam are required to achieve anxiolysis in the mouse line 
and that the anxiolytic effect might have been obscured by sedation (Morris et al., 2006). An 
α3-selective inverse agonist has been reported to be anxiogenic (Collins et al., 2002), whereas 
an agonist selectively interacting with α3-comprising receptors has been shown to be 
anxiolytic in vivo (Dias et al., 2005). Another compound with activity on α2, α3 and α5 
containing receptors while displaying no activity on α1 containing receptors has been shown 
to reduce anxiety in both wild type and α2H101R mice. These findings underline the role of 
α3- containing receptors in anxiolysis. A contribution of α5-containing receptors to anxiolysis 
is unlikely (Collinson et al., 2002; Morris et al., 2006). 
 
2.1.3.5 GABAA RECEPTORS MEDIATING MYORELAXATION 
There is evidence that the myorelaxant effects of benzodiazepines are mainly mediated by 
GABAA receptors containing α2 subunits (Crestani et al., 2001), however at high doses α3 
containing receptors are also involved (Mohler et al., 2001). 
 
2.1.3.6 GABAA RECEPTORS MEDIATING ANALGESIC EFFECTS  
A common concomitant phenomenon of inflammatory diseases and neuropathic insults is 
severe and debilitating pain that might become chronic and that does not respond to analgesic 
treatment. An impaired synaptic inhibition in the spinal dorsal horn is assumed to contribute 
essentially to this phenomenon. Enhancement of spinal GABAergic neurotransmission via 
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enhancement of GABAA receptors might, thus, be a promising approach. In the spinal dorsal 
horn presumably GABAA receptors containing α2 and/or α3 containing receptors are 
expressed. Selectively targeting of these receptors may induce analgesia (Knabl et al., 2008). 
A benzodiazepine site ligand selectively interacting with GABAA receptors containing α2, α3 
or α5 subunits is highly efficient in relieving inflammatory and neuropathic pain, without 
exhibiting unwanted sedation, motor impairment and tolerance development (Knabl et al., 
2008). 
 
2.1.4 MODULATION OF GABAA RECEPTORS CONTAINING γ1 SUBUNITS 
Substitution of γ2 by γ1 or γ3 drastically alters the effects of benzodiazepines on GABAA 
receptors (Hevers and Luddens, 1998). γ1 and γ3 subunits are apparently less abundant in the 
central nervous system compared to γ2  (Pirker et al., 2000; Sieghart and Sperk, 2002). The 
pharmacology of γ1 and γ3 containing receptors is, however, less well understood compared to 
γ2 containing subtypes. Ymer et al. (1990) reported a reduced affinity for the benzodiazepine 
antagonist flumazenil and the inverse agonist DMCM (methyl-6,7-dimethoxy-4-ethyl-β-
carboline) in α1β1γ1 receptors. Ro 15-4513, β-CCM and DMCM changed their direction of 
action and became positive modulators of α1/2/3β1γ1 receptors compared to α1/2/3β1γ2 receptors. 
Our group investigated the interaction of 21 ligands of the benzodiazepine binding site with 
α1β2γ1 receptors. Triazolam, clotiazepam, midazolam, CGS 20265 and CGS 9896 were 
identified as potent and efficient modulators of GABAA receptors containing γ1 subunits 
(Khom et al., 2006). 
 
2.2 BARBITURATES 
After introduction of barbiturates in medical practice in 1934, these drugs interact with 
multiple targets in the central nervous system. Besides inhibition of excitatory amino acid-
gated receptors (Marszalec and Narahasi, 1993) and voltage-gated Ca2+ channels (Leslie, 
1987) GABAA receptors represent the major target for hypnotic-anaesthetic barbiturates such 
as pentobarbital and phenobarbital (Rho et al., 1996).  There is evidence that barbiturates 
exert three different actions on GABAA receptors: at low concentrations they potentiate 
agonist-induced currents (Macdonald and Barker, 1979), at higher concentrations they 
directly activate the receptor in the absence of an agonist (Yang and Olsen, 1987) and at even 
higher concentrations, barbiturates block GABAA receptors (Drafts and Fisher, 2006). 
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On the single channel level, barbiturates increase the mean open time of GABA-activated 
channels (Macdonald et al., 1989). Interestingly, the kinetic properties of GABA-induced 
currents in the presence of modulating concentrations of pentobarbital differ from GABA-
induced currents in the absence of pentobarbital (Rho et al., 1996). 
So far, binding of barbiturates to GABAA receptors could not be investigated, as barbiturates 
exhibit a low receptor affinity (Sieghart, 1995). Barbiturates enhance  [3H]GABA, 
[3H]muscimol and [3H]flunitrazepam binding (Olsen, 1982). Moreover, in contrast to 
convulsants such as picrotoxinin, TBPS, pentamethylenetetrazole that inhibit [35H]TBPS 
binding competitively, central depressant barbiturates allosterically modulate the [35H]TBPS 
binding site. Thus, the barbiturate binding site is presumably distinct from the GABA, 
benzodiazepine or DHP/TBPS binding site (Sieghart, 1995). 
The three distinct actions of barbiturates on GABAA receptors are dependent on the subunit 
composition (Thompson et al., 1996). Modulation and direct activation are apparently 
structurally separable (Dalziel et al., 1999; Chang et al., 2003). In general, there is evidence 
that α and β subunit isoforms influence the modulation of GABAA receptors by barbiturates 
(Thompson et al., 1996). Receptors comprising β2 or β3 subunits are more efficiently 
modulated by barbiturates than those containing β1 subunits (Drafts and Fisher, 2006). 
Mutation T262Q in the β1 subunit abolishes modulation of GABAA receptors by barbiturates. 
This, however, does not affect direct activation (Dalziel et al., 1999) as well as mutation 
β2G219F eliminates the potentiating effect of pentobarbital (Carlson et al., 2000).  
β3 containing GABAA receptors seem to contribute to some of the in vivo effects of 
barbiturates. β3N265M mice showed a strongly reduced duration of the loss of rightening 
reflex and lacked completely the loss of hindlimb withdrawal reflex (Zeller et al., 2007). 
 
2.2.1 DIRECT ACTIVATION OF GABAA RECEPTORS BY BARBITURATES 
Several point mutations in the β2 subunit (mutation of residues β2Y157, β2T160, β2T202 and 
β2Y205) abolished activation of GABAA receptors by GABA, however did not affect direct 
activation by barbiturates. This suggests the existence of two distinct sites for activation by 
GABA and barbiturates (Amin and Weiss, 1993; Rho et al., 1996). Bicuculline and picrotoxin 
block pentobarbital-induced currents, the latter, however, with higher efficiency. Bicuculline 
was assumed to inhibit the action of pentobarbital allosterically. Upon rapid termination of 
barbiturate perfusion of cells expressing GABAA receptors a transient increase (rebound) in 
both pentobarbital-induced or pentobarbital-potentiated GABA-induced current was observed, 
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that could result from a rapid dissociation from a low-affinity channel blocking site facing a 
relatively slow relaxation of the agonist effect (Rho et al., 1996). 
The α-subunit isoform of GABAA receptors substantially affects direct activation by 
barbiturates. Pentobarbital gates most efficiently GABAA receptors comprising α6 subunits 
(Thompson et al., 1996). A single amino acid residue located in the N-terminal domain of the 
α6 subunit (α6Thr69) regulates the efficacy of pentobarbital. When mutated to either lysine, 
histidine or isoleucine this residue drastically reduces the ability of pentobarbital to activate 
GABAA receptors directly. There is evidence that residue α6Thr69 lies at the end of loop D 
(Drafts and Fisher, 2006). The β subunit is assumed to contribute to the GABA binding site 
via its “plus side” including loops A and B and the α subunit forms the “minus side” by 
providing loops D and E (Ernst et al., 2005). Thus, α6Thr69 is suggested to play an important 
role in pentobarbital binding or in transducing the binding signal (Drafts and Fisher, 2006). 
 
2.3 GENERAL AND VOLATILE ANAESTHETICS 
The ways in which general anaesthetics produce their effects on the CNS are still not 
completely understood. Historically, general anaesthetics were considered to interfere with 
membrane fluidity, thereby affecting cellular events. Recent evidence suggests that 
anaesthetics interact with proteins within the plasma membrane (Franks and Liebs, 1994). 
Several ion channels are modulated by anaesthetics at clinically relevant concentrations 
(Krasowski and Harrison, 1999; Thompson and Wafford, 2001). The GABAergic system is 
considered to be a likely target for multiple anaesthetics (Reynolds et al., 2003). Only  
ketamine, α2-adrenergic agonists and xenon target receptors other than GABAA channels 
(Franks et al., 1998; Belelli et al., 1999; Miller et al., 2002). In analogy to barbiturates (see 
chapter 2.2) anaesthetics such as propofol or isoflurane exert three distinct effects on GABAA 
receptors: at clinically relevant concentrations they enhance GABA-induced chloride currents, 
at concentrations higher than those required for potentiation they directly gate GABAA 
receptors in the absence of GABA and at still higher concentrations, they block both GABA- 
and anaesthetic-induced currents (Orser et al., 1994; Belelli et al., 1999; Bali and Akabas, 
2004; Hemmings et al., 2005; Rosen et al., 2007). The different actions may also reflect 
distinct binding sites. Support for this hypothesis comes from the observation that the 
conformation of segment M3 and the surrounding domains are distinct in the presence of 
enhancing or directly gating concentrations of propofol (Williams and Akabas, 2002). Direct 
activation, at least for some anaesthetics, is apparently mediated via a binding site distinct 
from the GABA binding pocket (Rosen et al., 2007). Single channel studies suggest that 
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general anaesthetics and GABA induce a similar conductance, however infer different 
kinetics (Jackson et al., 1982). The open-state structure of the channel seems to be similar in 
the presence of either general anaesthetics or GABA. Upon activation by GABA residues 
α1T261 and β1T256 are brought in close proximity. This effect is not seen at potentiating 
concentrations of anaesthetics, but during direct activation induced by anaesthetics (Rosen et 
al., 2007). There is evidence that the occupancy of these sites stabilises different receptor 
states or an ensemble of receptor states (Rosen et al., 2007). Single channel studies revealed 
that- in analogy to barbiturates- general anaesthetics increase the channel mean open time 
(Twyman and Macdonald, 1992).  
Several amino acid residues involved in mediating the effects of both intravenous and volatile 
anaesthetics have been identified: mutations in the α-subunit affect the effects of volatile 
anaesthetic, while intravenous anaesthetics are sensitive to mutations in the β-subunit (Belelli 
et al., 1997; Mihic et al., 1997; Mascia et al., 2000; Krasowski et al., 2001; Nishikawa et al., 
2002).  
Insights into putative anaesthetic binding sites were provided by studies on mutant receptors 
or chimeras (Williams and Akabas, 2002; Bali and Akabas, 2004). However, it is almost 
indistinguishable to judge whether these residues are involved in ligand binding or in 
transducing the effect (Colquhoun, 1998). Despite these limitations there is evidence that 
anaesthetics interact with GABAA receptors in a region close to the extracellular end of 
membrane spanning domains (Belelli et al., 1999; Krasowski and Harrison, 1999; Miller, 
2002). This region has been suggested to be lined by the non-channel lining face of the M2 
segment (Xu and Akabas, 1996) and by residues from the M3 as well as from M1 and M4 
(Bali and Akabas, 2004). 
 
2.3.1 ETOMIDATE 
Etomidate enhances chloride currents through GABAA receptors at clinically relevant 
concentrations (Belelli et al., 2003). The estimated effective plasma levels of etomidate 
correlate well with the concentrations required for modulation of GABAA receptors 
(Krasowski and Harrison, 1999). 
The activity of etomidate is enantioselective and highly dependent on β2 or β3 subunit 
incorporation into GABAA receptors (Hill-Venning et al., 1997; Belelli et al., 2003). This 
selectivity is apparently conferred by an asparagine residue in position 265 (β2N265) in the 
M2 domain, which distinguishes this ligand from pentobarbital (McGurk et al., 1998; Belelli 
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et al., 2003). The same residue is crucial for the activity of loreclezole (Wingrove et al., 1994; 
see also chapter 2.7.1.). 
In vivo, N265 also determines the β-selectivity for etomidate (Belelli et al., 1997). Knock-in 
mice (β3S265M) showed a reduced sensitivity to anaesthetic effects of etomidate and propofol 
(Jurd et al., 2003). It remained uncertain, whether these residues contribute to anaesthetic 
binding or allosteric modulation of gating. By means of a photoreactive analogue of etomidate 
([3H]azietomidate) amino acids contributing to a putative anaesthetic binding site were 
identified. The identified residues, α1M236 and β1M286, are likely to border a pocket in the 
transmembrane domain (located at the same subunit interfaces as the GABA binding site) (Li 
et al., 2006). The subunit stoichiometry of 2α:2β:1γ (Chang et al., 1996; Tretter et al., 1997) 
and the arrangement of GABAA receptor subunits (Baumann et al., 2002) predicts two 

















Proposed orientation of etomidate in its binding pocket 
The N3 atom of etomidate and the side-chain amine group of β2Asn265 in the M2 region 
presumably form a hydrogen-bond. The imidazole ring of Trp237 in the M1 region and the 
phenyl group of etomidate were proposed to interact via a π–π stacking. Other residues 




Figure 10 Illustration of an azietomidate binding 
site in a GABAA receptor homology model.
Pockets in proximity of the binding sites for 
etomidate (maroon), GABA (purple), and 








The intravenous anaesthetic propofol increases the chloride conductance and the open 
probability of GABAA channels (Hales and Lambert, 1991). As reported for other 
anaesthetics e.g. methohexital (Koltchine et al., 1996), etomidate (Uchida et al., 1995; Sanna 
et al., 1997), alphaxalone (Horne et al., 1993), or isoflurane (Harrison et al., 1993; Mihic et 
al., 1994), propofol action does not require γ subunits (Jones et al., 1995). There is evidence 
for an involvement of the segment M3 in propofol binding (Bali and Akabas, 2003). β2M286 
has been suggested to play a major role, as mutating this residue abolished IGABA enhancement 
without affecting direct activation (Krasowski et al., 1998). Mutation of β2Tyr157, a residue 
located in the GABA binding site, decreases the direct receptor activation by propofol, but did 
not affect the potentiating activity (Fukami et al., 1999). These findings suggest that propofol 
acts via two distinct sites on GABAA receptors (Bali and Akabas, 2003). Residues potentially 
contributing to the binding site for propofol on GABAA receptors were identified by analysing 
the crystal structure of two propofol molecules bound to human serum albumin. The phenolic 
hydroxylgroup bonds to a backbone carbonyl at one site and a serine hydroxyl at the other 
side (Bali and Akabas, 2003). 
Campagna-Slater and Weaver (2007) proposed that propofol on GABAA receptors is located 
in close proximity to the membrane-extracellular interface between M1 and M4, close to M3. 
The propofol hydroxyl-hydrogen atom might form a bond to the side-chain carbonyl group of 
β2Gln224. Moreover, a π–π stacking interaction has been suggested to occur between the 
phenyl ring of residue Tyr448 and in addition a weak hydrogen-bond between the Tyr448 
side-chain hydroxyl hydrogen atom and the propofol hydroxyl oxygen atom. Residues Gln224 
and Tyr448 are conserved in all β subunit isoforms. This is consistent with the lack of β-
subunit specificity of propofol. Other residues that have been suggested to interact with 
propofol molecule include Leu223, Thr225 and Tyr226 in M1, Leu285, Phe289 and Phe293 
in M3, and Tyr444 and Trp445 in M4. The binding cavity for propofol has been suggested to 
open between the M1 and M4 segments on the extracellular side of the membrane, thus not 
the whole molecule is buried in the membrane, but one of the isopropyl groups might extend 
out in this opening (Campagna-Slater and Weaver, 2007). Mutation of residue β2Y444W 
selectively suppresses the ability of propofol to enhance GABAA receptor function while 
normal sensitivity to etomidate and pregnenolone is retained. Propofol’s reduced sensitivity 
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in this mutant is in line with the loss of a hydrogen bond within the propofol binding site  















In vivo, β3M265S knock-in mice propofol failed to show any anaesthetic effect (Jurd et al., 
2003), although the action of propofol is independent of a particular β-subunit variant (Hill-
Venning et al., 1997). 
 
2.3.3 VOLATILE ANAESTHETICS  
The CNS depressant effects of volatile anaesthetics have first been assumed to be non-specific 
actions (Janoff et al., 1981). At clinically relevant concentrations GABAA and glycine 
receptor mediated currents are enhanced (Franks and Lieb, 1994). Interestingly, the effect on 
GABAC receptors has been shown to be less pronounced (Mihic et al., 1997). 
The size of the putative binding site for volatile anesthetics has been proposed to range 
between 250 and 370Å. Amino acids αL232, αS270, and αA291 (M1, M2, and M3, 
respectively) define a binding cavity for small anesthetic molecules (Jenkins et al., 2001). 
Jenkins et al. (2001) reported later that the data for mutants L232F and S270H suggest that the 
anesthetics do not fit into the putative binding cavity in an identical manner. Mutation L232F 
did not affect isoflurane, while the enhancement of halothane was reduced. Halothane (unlike 
isoflurane) was active at the S270H mutant, suggesting a closer contact with L232 than 
isoflurane, which may instead be in close contact to S270. Introducing bulkier residues in 
 
Figure 11 The docked propofol molecule in the putative 
binding site on the β2 subunit on GABAA (Campagna-
Slater and Weaver, 2007). 
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these positions results in a loss of sensitivity to both isoflurane and halothane (Jenkins et al., 
2001). 
αSer270 is likely to be involved in binding ethanol and isoflurane, as the GABAA receptors 
carrying the α2S270C mutation were irreversibly enhanced by an alkanethiol anesthetic and 
the sulfhydryl reagent propyl methanethiosulfonate. The alkylated the α2S270C mutant was 
insensitive to isoflurane (Mascia et al., 2000) suggesting that α2S270 is indeed involved in the 
binding of volatile anaesthetics such as isoflurane (Jenkins et al., 2001). Isoflurane and 
sevoflurane evoke currents in the absence of GABA and similar to picrotoxin induce an open-
channel block (Hasenender et al., 2002). Isoflurane and picrotoxin even might share a 
common binding site in the channel pore (Edwards and Lees, 1997), as picrotoxin suppresses 
the induction of a tail current on the removal of isoflurane, whereas bicuculline lacks this 




   In the 1940s, metabolites of the hormone progesterone were identified as potent sedatives and 
anaesthetics (Seyle, 1941; Seyle, 1942). As the central depressant effect of such steroids 
occurs with a rapid time course, a genomic mechanism of action was excluded (Lambert et 
al., 2003).  
   Steroids have later been established as highly selective and potent positive allosteric 
modulators of GABAA receptors in multiple in-vitro experiments (Lambert et al., 2003). 
Although endocrine glands such as ovaries and adrenals represent relevant sources of 
endogenous GABAA receptor active steroids, there is, however, evidence that certain neurons 
and glial cells possess the enzyme repertoire required for local synthesis of steroids. The brain 
may thus function in a paracrine fashion by locally influencing inhibitory neurotransmission. 
The mechanism by which neurosteroids are released in-vivo from neurons and glia is yet not 
fully understood (Lambert et al., 2003). Steroids do not affect GABAA channel single 
conductance, but they greatly facilitate the open state of GABAA receptors (Lambert et al., 
1995). 
Endogenous neurosteroids are potent modulators of all GABAA receptor isoforms. GABAA 
receptors are sensitive to low nanomolar concentrations of neurosteroids that have been 
shown to occur physiologically. At such concentrations (observed during stress, alcohol 
intoxication and oestrus) they potentiate GABA-induced currents, while at submicromolar to 
micromolar concentrations, which occur e.g during parturition, they gate the channel directly 
32 
(Lambert et al., 2003; Hosie et al., 2006). Thus, the major inhibitory neurotransmitter receptor 
in the mammalian CNS might be affected by both remote endocrine and local paracrine “fine-
tuning” by neuroactive steroids (Lambert et al., 2003). In-vivo neuroactive steroids exhibit a 
behavioural profile resembling that of other positive allosteric modulators of GABAA 
channels. Neurosteroids are anxiolytic, anticonvulsant and sedative, and at higher 
concentrations neuroactive steroids induce general anaesthesia (Rupprecht, 2003). 
To regulate GABAA receptor function neurosteroids require a C3α hydroxylgroup on the A-
ring and a C20 ketone in the D-ring, indicating possible hydrogen bonding with polar and/or 
charged residues (Harrison et al., 1987). 
 
2.4.1 INFLUENCE OF THE SUBUNIT COMPOSITION ON NEUROSTEROID  
          ACTION ON GABAA RECEPTORS 
In contrast to benzodiazepines (Sieghart, 1994; Sieghart, 1995) the modulatory effect by 
neurosteroids does not depend on a particular α- isoform (α1-6) (Belelli et al., 2002). 3α,5β-
5β-pregnan-3α-ol-20-one (3α, 5β- THPROG) produces a 6-7 fold enhancement of IGABA. 
However, on receptors containing α6 subunits the enhancement was markedly stronger (12-
fold), suggesting a preference of neuroactive steroids for receptors containing α6 subunits. 
The apparent affinity for neuroactive steroids is not affected by the α-isoform present (Belelli 
et al., 2002). 
Small differences in apparent affinities might be of relevance, however, considering the 
concentrations of neurosteroids known to occur physiologically (Lambert et al., 2003). The 
relative insensitivity of α4β1γ2 receptors is of particular interest, since following progesterone 
withdrawal expression of this receptor subtype is increased. This up-regulation is apparently 
not mediated by progesterone itself, but by the GABAA receptor active metabolite 3α, 5β- 
THPROG (Follesa et al., 2001). The steroid sensitivity of GABAA channels containing α4 
subunits is strongly dependent on the subunits co-expressed, as α4βδ containing receptors are 
highly sensitive for neurosteroids (Belelli et al., 2002). 
The β-variant has only little influence on the modulatory effect of neurosteroids (Sanna et al., 
1997 Belelli et al., 2002, Lambert et al., 2003) and expression of a γ-subunit is not a prequisite 
for neurosteroid modulation of GABAA receptors. Replacement of γ-subunits by δ-subunits 
has been demonstrated to increase the sensitivity of GABAA receptors for steroids (Belelli et 
al., 2002). Receptors composed of α4, β3 and δ (a subunit combination expressed in the 
thalamus) are highly sensitive to steroid modulation compared to the corresponding γ2- 
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containing receptor (Belelli et al., 2002). In δ(-/-) mice neurosteroids fail to show 
anticonvulsant and anaesthetic properties (Mihalek et al., 1999; Lambert et al., 2003). There is 
evidence that receptors containing ε-subunits are spontaneously active. GABAA receptors 
containing ε-subunits were directly activated by steroids. These results are, however, difficult 
to interpret, because it is not clear whether the observed effect is due to direct gating of 
GABAA channels or a modulation of the spontaneous channel activity (Belelli et al., 2002; 
Thompson et al., 2002; Lambert et al., 2003). 
 
2.4.2 THE NEUROSTEROID BINDING SITE 
An azide derivative of 3α, 5β- THPROG did not directly label GABAA receptor subunits, but 
was incorporated into the voltage-dependent anion channel-1 (VDAC-1) (Darbandi-Tonkabon 
et al., 2003; Lambert et al., 2003). 
Insights into the putative binding site of neurosteroids on GABAA receptors have been gained 
in a studied performed by Hosie et al. (2006), who replaced the murine M1 domain by the M1 
domain of the Drosophila melanogaster RDL (resistance to dieldrin) GABAA receptor (RDL 
GABAA receptors exert a low sensitivity to potentiation and lacks direct activation by 
neurosteroids). Substitution of polar residues in the α1 subunit by the homologous RDL 
positions identified αThr236 and αGln241 as crucial determinants of steroid action. Mutation 
αThr236Ile reduced receptor activation by α-tetrahydrodeoxycorticosterone (THDOC) and 
allopregnalone (ALLOP), whereas mutating αGln241 to Trp reduced the IGABA potentiation 
and decreased the apparent agonist efficacy without affecting the half-maximal receptor 
activation. The effects of neurosteroids on GABAA channel function i.e. potentiation of 










In analogy to a homology model of the transmembrane region of the nAch-receptor it was 
assumed that Thr236 lies on the receptor surface of the GABAA receptor close to the β/α 
Figure 12 Model of the transmembrane 
domains of GABAA receptors with a bound 
THDOC molecule to αThr 236 and βTyr 284  
(Hosie et al., 2006) 
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subunit interface (the same interface in which GABA binds). This residue would thus be 
accessible to hydrophobic molecules in the membrane. Gln241 lies at the base of a putative 
cavity between the α-subunits M1 and M4 domains. Upon receptor activation the depth and 
the volume of this cavity apparently increase and thus would allow the neurosteroid to bind to 
αGln241 and to stabilize the receptor in an active state. The relative locations of αThr236 and 
αGln241 on opposite faces of the M1 helix strongly suggest that they will contribute to 
steroid binding at 2 distinct sites. The neurosteroid’s C20 ketone group can only participate as 
hydrogen-bond acceptor, whereas the C3α-hydroxylgroup can donate a hydrogen bond to Gln 
241. The C20 ketone might also interact with the Asn407 and Tyr410 (M4 of the α1 subunit). 
Both of them can donate hydrogen bonds. Introduction of hydrophobic amino acids 
αAsn407Ala and αTyr410Phe reduces neurosteroid potency (Hosie et al., 2006). However, 
the mutation αAsn407Ala caused a greater reduction in the potency of THDOC (approx. 10-
fold) than in that of ALLOP (approx. 3-fold), while αTyr410Phe solely reduced the potency 
of THDOC, which is consistent with the coordination of the oxygen moieties on the 
neurosteroid’s D ring, the only region where THDOC and ALLOP structurally differ. 
As mutation αGln241Trp did not only abolish the potentiating effect, but also disrupted the 
neurosteroid-induced direct activation, it was assumed that binding to αThr236-βTyr284 only 
elicits low-efficiency activation. High-efficiency activation depends on further binding to 










It is thus assumed that 2 discrete groups of residues in the GABAA receptor transmembrane 
domains mediate the effects of neurosteroids: binding to αThr236 and βTyr284 initiates the 
activation, while via αGln241 and αAsn407 the potentiation of responses to GABA and/or 
neurosteroids are mediated. Given the stoichiometry of GABAA receptors, two copies of these 
binding sites are apparently present. The above-mentioned residues are conserved throughout 
Figure 13 Illustration of the α subunit’s transmembrane domains, 
showing α Gln 241, α Asn 407 and α Tyr 410 docking with a 
THDOC molecule (Hosie et al., 2006).  
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the α and β subunits, thus they are ideally placed to mediate neurosteroid modulation and 
activation of all GABAA receptor subtypes (Hosie et al., 2006). 
 
2.5 ETHANOL 
The effects of ethanol on humans are well known. At low blood concentrations ethanol 
induces a feeling of euphoria and disinhibition, with increasing levels of ethanol motor 
function becomes impaired and speech becomes slurred. At blood ethanol concentrations 
reaching between 200 and 300 mg/dl blood, vomiting and falling into stupor can occur. Blood 
concentrations exceeding 300 mg/dl can induce coma, and at even higher concentrations 
(500mg/dl), there is a potential danger of respiratory failure and death (Davies, 2003). 
Until it was shown that ethanol binds to specific proteins, in particular to ligand-gated ion 
channels and voltage-gated Ca2+-channels, the lipid theory has been widely accepted 
(Tabakoff and Hoffmann, 1996; Davies, 2003). 
In native receptors from rat brain microsacs and synpatoneurosoms enhancement of IGABA by 
ethanol was shown for the first time. Ethanol exposure augmented the GABA-gated chloride 
uptake by 260% (Suzdak and Paul, 1987). Later, Wafford and Whiting (1992) showed that 
potentiation of IGABA by ethanol was critically dependent on the presence of the γ2L splice 
variant in α1β2γ2, whereas others failed to reproduce this finding (Sigel et al., 1993, Zhai et 
al., 1998). GABAA receptors containing α4/6, β3 and δ subunits, those known to mediate tonic 
currents, have been described to be exceptionally sensitive to low ethanol concentrations 
(Wallner et al., 2003; Hanchar et al., 2005, Santhakumar et al., 2007). GABAA receptor δ-
subunit knockout (δ-/-) mice show multiple defects in behavioural respones to ethanol 
(Mihalek et al., 2001). The α6R100Q mutation, identified in alcohol-tolerant rats, is sufficient 
to induce ethanol hypersensitivity, to confer supersensitivity to tonic currents in rat cerebellar 
granule cells and to dramatically increase the ethanol sensitivity of recombinantly expressed 
receptors (α6R100Qβ3δ) (Hanchar et al., 2005). Therefore, an amino acid residue important 
for BZ sensitivity is also critical for low-dose ethanol sensitivity of α6 containing GABAA 
receptors (Wallner et al., 2006). The imidazobenzodiazepine Ro15-4516, a structural 
analogue of the clinically used benzodiazepine antagonist flumazenil, is also an ethanol 
antagonist (Bonetti et al., 1988). 
The question whether Ro15-4513 ‘s alcohol antagonism is related to a specific alcohol 
counteracting action or due to a non-specific functional antagonism or due to the weak inverse 
agonistic activity of Ro15-4513 on certain GABAA receptor subtypes has been overcome by 
identification of a high affinity binding site on α4β3δ receptors. At anaesthetic and potentially 
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lethal concentrations (≥ 100mM), however, an additional Ro15-4513-insensitive component 
of ethanol enhancement occurs. This component is abolished by the mutation β3N265M 
(Wallner et al., 2006). Ethanol increases the frequency and the duration of single-channel 
openings, and further augments channel bursts and burst duration and reduces the fraction of 
time that the channel remains in the closed state (Tatebayashi et al., 1998). 
Various alcohols including methanol, butanol, hexanol, octanol, decanol and dodecanol 
enhance GABA-gated currents. A correlation between chain length and potency has been 
suggested, as ethanol potency increases with the number of carbon atoms in the backbone. 
However, alcohols possessing more than 12 carbon atoms do not affect GABA-gated currents 
anymore (Davies, 2003), indicating that they share a common binding site with a defined 
volume that accommodates only alcohol molecules with chain lengths not exceeding 12 
carbon atoms (Nakahiro et al., 1996). 
 
2.6 CATIONS MODULATING GABAA RECEPTOR FUNCTION 
There is evidence for specific binding sites for divalent cations on ligand-gated ion channels. 
Calcium and other divalent cations have been shown to enhance or inhibit [3H] GABA or [3H] 
benzodiazepine binding (Lo and Snyder, 1983; Schwartz et al., 1994), though a direct 
interaction of calcium with GABAA channels has not be shown (Schwartz et al., 1994). 
Magnesium attenuates neuronal excitability by a blockade of NMDA receptors under resting 
conditions (Mayer et al., 1984). Magnesium, thus, exhibits neuroprotective actions following 
seizure activity and cerebral ischemia (Tsuda et al., 1991; Schwartz et al., 1994). Magnesium 
also reduces basal and GABA-inhibited [35S] TBPS binding to GABAA receptors in a dose-
dependent manner up to a concentration of 1mM. Concentrations exceeding 10 mM enhanced 
the binding. The effect of magnesium does not depend on the presence of a γ-subunit 
(Moykkynen et al., 2001). 
Another cation of special interest in neuronal activity is zinc, being present in the cerebral 
cortex and the hippocampus, both enhancing and inhibiting neuronal excitability (Westbrook 
and Mayer, 1987; Xie and Smart, 1991). Zinc has been demonstrated to interact with a 
binding site located at the extracellular domain of NMDA receptors, thus inhibiting NMDA 
function (Westbrook and Mayer, 1987).   
The blocking effect of Zn2+ ions on GABAA receptor has been intensively studied revealing a 
dependence on the species and maturity of the neurons as well as on the GABAA receptor 
subunit composition (Draguhn et al., 1990; Smart et al., 1991). GABAA receptors comprising 
α6 and β3 subunits have been shown to be most sensitive to zinc (Burgard et al., 1996; 
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Knoflach et al., 1996; Saxena and MacDonald, 1996). Replacement of the δ subunit by a γ 
subunit as well as replacement of α6 by α1 greatly reduces inhibition of GABAA receptors by 
Zn2+ (Draguhn et al., 1990; Saxena and MacDonald, 1996; Korpi et al., 2002). Comparison of 
zinc’s inhibitory effects on GABAA receptors comprising different α subunits revealed a 
higher sensitivity but lower efficacy of zinc on GABAA receptors containing α1 subunits than 
on those containing α2 or α3 subunits (White and Gurley, 1995). It is assumed that the zinc 
binding site is formed by different subunits (Korpi et al., 2002). Wooltorton et al. (1997) 
reported that Zn2+ inhibition is significantly reduced by the mutation H292A in the M2 region 
in both homomeric β3 and β1 receptors indicating an involvement of this residue, that is 
located in the putative channel-lining M2 region, in determining zinc sensitivity (Korpi et al., 
2002).  Another amino acid residue located at the extracellular end of the M2 region (β3H267) 
also contributes to zinc modulation of GABAA receptors (Hosie et al., 2003).  
A major determinant of Zn2+ insensitivity for GABAA receptors containing γ subunits (N156) 
was found in the N-terminal extracellular domain of γ2L subunits. This residue is highy 
conserved in all GABAA receptor subunit families except pi. Interestingly, this amino acid is 
adjacent to H101 in the α1 subunit, which is required for benzodiazepine sensitivity in ternary 
αβγ receptors (Nagaya and MacDonald, 2001). Other amino acids contributing to zinc 
insensitivity include residues γ2LS278, γ2LT279 and γ2LI280 in the outer mouth of the M2 
region as well as residue γ2LK285 in the extracellular M2-M3 linker region (Korpi et al., 
2002).  
 Lanthanum enhances GABA-gated currents neither via interaction with the benzodiazepine, 
barbiturate nor picrotoxin binding site, as no competition with chlordiazepoxid, pentobarbital 
or picrotoxin was observed (Ma and Narahashi, 1993). Lanthanum enhanced IGABA through 
α1β2γ2 receptors, whereas a drastically reduced efficiency was observed for α1β2 receptors (Im 
et al., 1992). 
Copper inhibits GABA-induced currents in a non-competetive manner. The effect of copper 
cannot be influenced by cations such as lanthanum. There is evidence that zinc antagonizes 
the action of copper dose-dependently, suggesting that they share a common binding site. This 
binding site has been suggested to be located at or close to the external mouth of the channel 





2.7 OTHER MODULATORS OF GABAA RECEPTORS 
2.7.1 LORECLEZOLE 
Loreclezole is broad-spectrum anticonvulsant agent that has been shown to be effective 
against generalized absence seizures and tonic-clonic convulsions (Ghiani et al., 1996). 
Loreclezole enhances the effect of GABA by interacting with a specific modulatory site on 
the β-subunit. A 300-fold higher affinity for GABAA receptors containing β2 or β3 subunits 
over those comprising β1 subunits was established (Wingrove et al., 1994). A single amino 
acid residue in the β2 subunit (β2N289 and β3N290) was identified as crucial determinant for 
conferring loreclezole sensitivity. Mutation of this residue to the corresponding residue in the 
β1 subunit (β1S290) abolishes the effect of loreclezole (Wingrove et al., 1994).  
 
2.7.2 MEFENAMIC ACID 
The non-steroidal antiphlogistic mefenamic acid exhibits anticonvulsant and proconvulsant 
effects. There is evidence that this drug enhances IGABA through α1β2γ2 receptors. However, it 
is inactive on the corresponding β1 subunit containing subtype. Mefenamic acid gates α1β2/3 
directly, but blocks α1β1 receptors. The positive modulatory action of mefenamic acid is 
determined by residue N290. When this position was mutated to serine (β2N290S) the 
positively modulating effect is abolished. The reverse mutation in the β1 subunit (β1S290N) 
induces sensitivity for mefenamic acid. Thus, positive allosteric modulation, direct activation 
and inhibition are determined solely by the β-subunit variant present, as shown for 
homomeric β1 and β3 receptors (Halliwell et al., 1999). 
 
2.7.3 CLOZAPINE 
Clozapine is an atypical neuroleptic that inhibits GABAA receptors in brain vesicles with 
particular high efficiency in cerebrocortical and hippocampal areas. Clozapine has been 
demonstrated to block [3H]muscimol and [3H]SR 95531 binding. Receptors composed of α1, 
β2 and γ2 subunits are sensitive to the antagonism by clozapine, whereas recombinant α6β2/3γ2 
receptors are not inhibited. The α6β1γ2 subtype is however sensitive for clozapine, indicating 
that the effect of clozapine dependent on the β- subunit (in the order β1>β2>β3). The effect of 
clozapine is not mediated via the benzodiazepine binding site, as flumazenil failed to block 
the effect of clozapine. It is assumed that clozapine blocks most GABAA receptors. The 
GABAA antagonism of clozapine is not shared by other neuroleptics such as haloperidol. The 
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effect of clozapine on GABAA receptors might account for the enhanced seizure susceptibility 
associated with clozapine treatment (Korpi et al., 1995). 
 
2.7.4 FUROSEMIDE 
Furosemide blocks GABAA receptors directly, an effect that is strongly dependent on the 
subunit composition (α6 and β2/3) (Korpi and Luddens, 1997). Furosemide antagonism does 
not depend on the presence of a γ or δ-subunit. Furosemide antagonism is not detectable in 
hippocampal and thalamic areas, although a modulation of α4β2γ2 receptors has been shown 
(Knoflach et al., 1996; Korpi and Luddens, 1997). 
The mechanism of action, however, differs apparently from the mechanism of action of other 
compounds antagonizing the function of GABAA receptors. The effect of furosemide on 
GABAA receptors can be blocked by high concentrations of Ro5-4864 (Korpi and Lüddens, 
1997). In ANT rats (carrying point mutation α6R100Q; see also chapter 2.5.) the effect of 
furosemide was less pronounced. This point mutation does not account for the reduced 
activity, as furosemide antagonism was comparable on recombinant wild type and mutated 
GABAA receptors (α6R100Q) (Makela et al., 1996). Based on the observation that furosemide 
preferentially modulates GABAA receptors containing α6 subunits, molecular determinants for 
the activity of furosemide were identified: Mutation of I288T in the α6 subunit largely shifts 
the IC50 values (10-fold reduction). This residue is apparently located in the M1 domain, thus 
suggesting that M1 with the isoleucine residue might contribute to a putative binding site for 
furosemide (Thompson et al., 1999). The effect of furosemide is strongly dependent on the β-
subunit incorporated into the receptor and stronger effects on β2/3 containing receptors are 
observed compared to β1 containing channels (Korpi et al., 1995). Co-expression of β1S265M 
and β3N265S with α6 and γ2 subunits, respectively, showed that the effect of furosemide 
depends on the same residue as the action of loreclezole (see also chapter 2.7.1.).  
Residue αI288 is presumably located in M1 and residue β3N265 in the extracellular end of the 
M2 domain. These residues are likely to be located in close proximity at the extracellular end 
of the channel. In the closed state of the channel M1 segments might intercalate between M2 
segments at the extracellular end of the receptor. Upon activation of the receptors, the 
movements of the M1 and the M2 region might flip a gate (as proposed for the muscle 
nicotinic receptor (Akabas and Karlin, 1995)). It is assumed that furosemide by direct 
interaction with the M1 segment stabilizes the closed state of the gate of GABAA receptors 
(Thompson et al., 1999). 
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3. TONIC AND PHASIC INHIBITION  
Whereas phasic inhibitory synaptic neurotransmission is well characterized, there is also 
convincing evidence for tonic, non-synaptic communication (Macdonald et al., 2004). 
Low concentrations of ambient GABA apparently activate extrasynaptic receptors causing a 
small, but persistent chloride current, which results in tonic inhibition enabling the neuronal 
excitability to be regulated (Mody, 2001). α6-subunit containing receptors are found 
exclusively in cerebellar granule cells and the dorsal cochlear nucleus (Fritschy and Brunig. 
2003; Sieghart and Sperk, 2002). They can therefore not account for the high GABA 
sensitivity associated with tonic inhibition in hippocampal pyramidal cells. The observed high 
GABA potency indicates the presence of δ-subunit containing receptors (Mortensen and 
Smart, 2006), as recombinant α4β3δ receptors are highly sensitive to GABA (Brown et al., 
2002). 
αβ receptors have been shown to be at least 5-fold more sensitive to GABA than αβγ 
receptors (Baburin et al., 2008), raising the possibility that αβ receptors may also contribute 
to tonic inhibition. 
Mortensen and Smart (2006) have shown that GABAA receptors lacking δ or γ subunit are 
likely to be expressed in low numbers in the extrasynaptic membranes of pyramidal neurons.  
The extent to which extrasynaptic GABAA receptors are tonically active is affected by the 
GABAA receptor subtypes expressed and their affinity to GABA, the basal GABA 
concentration around the extrasynaptic domains e.g. due to a spillover from nearby 
GABAergic synapses and finally, the activity of GABA transporters that will regulate ambient 
GABA concentrations (Mortensen and Smart, 2006). Estimates of ambient GABA 
concentrations range from tens of nanomolar to a few micromolar (Lerma et al., 1986; 
Tossman et al., 1986). Endogenous GABA concentrations have apparently a highly non-
uniform distribution between the synaptic and extrasynaptic areas (Mortensen and Smart, 
2006). A variation in subunit composition of extrasynaptic receptors may include the α5 
subunit, which is expressed in high density in the hippocampus (Pirker et al., 2000) and shows 
a diffuse extrasynaptic distribution (Crestani et al., 2002). This would agree with recent 
evidence supporting an important role of α5βδ receptors in tonic inhibition in hippocampal 
pyramidal cells. The number of αβ receptors present in extrasynaptic receptors is rather low 





4. PATHOPHYSIOLOGICAL CONDITIONS ASSOCIATED WITH   
    IMPAIRED GABAERGIC NEUROTRANSMISSION 
GABA plays a major role in controlling the excitability of the brain. A disruption of the 
balance between excitatory and inhibitory neurotransmission is associated with multiple 
neurological disorders (Sieghart and Sperk, 2002). 
An enhancement of the GABAergic system is associated with anxiolysis, sedation, amnesia, 
ataxia and loss of consciousness, whereas a reduction of the inhibitory GABAergic 
neurotransmission results in arousal, anxiety, restlessness, insomnia, exaggerated reactivity, 
and even epileptic seizures (Mohler, 2006). Impaired GABAA receptor function is associated 
with neurological disorders such as insomnia, anxiety disorders, epilepsy and schizophrenia 
(Sieghart and Sperk, 2002; Mohler, 2006). 
 
4.1 INSOMNIA 
Insomnia represents the most common sleep disorder affecting almost 20-50% of older adults 
(McCrae et al., 2007). Individuals suffering from sleep disorders can be grouped into three 
categories: sleep onset insomnia, sleep maintenance insomnia and terminal insomnia 
(awaking early morning combined with inability to return to sleep) (Rosenberg, 2006). 
GABAergic neurotransmission contributes significantly to human sleep regulation (Agosto et 
al., 2008). Three different areas of the central nervous system are involved in regulating non 
rapid-eye-movement sleep. Sleep-promoting GABAergic neurons in the ventrolateral preoptic 
nucleus (VPLO) are assumed to be tonically inhibited via noradrenergic neurons located in 
the locus coeruleus of the pons, thus inhibition of neurons of the locus coeruleus results in 
activation of VLPO neurons and thus may induce sleep. Moreover, the subsequent release of 
GABA from VPLO neurons is assumed to inhibit wake-active histaminergic neurons in the 
tuberomammilary nucleus (TMN) of the hypothalamus. The inactivation of the TMN seems to 
play a crucial role for the sleep onset (Bateson, 2004). Moreover, in a patient suffering from 
chronic insomnia a mutation in the gene encoding for the β3 subunit was identified, the 
resulting subunit carrying in position 129 instead of an arginine a histidine residue 
(β3R129H). Analysis of the α1β3R129Hγ2 receptors showed a slower rate of the phase of 
desensitisation and a faster current deactivation compared to wild type α1β3γ2 receptors (Buhr 
et al., 2002), giving further evidence for an involvement of decreased GABAergic 




4.2 ANXIETY  
The precise pathogenesis underlying anxiety disorders is still not fully understood. Several 
distinct mechanisms apparently underlie different anxiety disorders, however, the GABAergic 
system is likely to be involved in anxiety. The GABAergic system has been suggested to play 
a major role in anxiety mainly based on the anxiety- relieving effects of benzodiazepines 
(Nutt and Malizia, 2001). γ2-knockout mice exhibit dysfunctions of the GABAergic system 
including reduced benzodiazepine binding and receptor clustering in the cerebral cortex and 
the hippocampus, regions that are associated with anxiogenesis in humans (Crestani et al., 
1999). Moreover, these mice reveal an increased behavioural reactivity to aversive stimuli and 
bias for threat cues, a behaviour that could be reversed by acute application of benzodiazepine 
site ligands. Thus, impaired GABAergic neurotransmission leading to enhanced harm-
avoidance behaviour and enhanced sensitivity to negative associations might predispose 
individuals to generalized anxiety disorder (GAD) and panic disorder (PD) (Crestani et al., 
1999; Nemeroff, 2003).  
In patients suffering from anxiety disorders a reduction in GABA levels and benzodiazepine 
binding was detected, while in individuals suffering from PD a 22% reduction of GABA 
levels in the total occipital cortex was observed (Goddard et al., 2001). A global decrease of 
GABAA receptor binding was found throughout the CNS in untreated individuals suffering 
from PD compared to controls, in particular with most pronounced decrease in the 
orbitofrontal cortex and right insula, two areas associated with mediation of anxiety (Malizia 
et al., 1998), moreover also in the left hippocampus and the precuneus benzodiazepine 
binding was reduced (Bremner et al., 2000a). 
In individuals suffering from posttraumatic stress disorder (PTSD) a similar reduction in 
GABAA receptor binding in the prefrontal cortex was observed, however without significant 
changes of binding in the pons, striatum, thalamus, cerecellum or midbrain compared to 
controls (Bremner et al., 2000b). 
Moreover, also individuals suffering form GAD showed a reduced GABAA receptor binding 
in the left temporal lobe (Tiihonen et al., 1997). 
 
4.3 EPILEPSY 
Epilepsy is a neurological disorder affecting more than 0.5% of mankind. Several genetic 
factors are assumed to play a pivotal role in the development of generalized epilepsies (IGEs) 
and in some partial epilepsies (Kaneko et al., 2002). Mutations associated with epilepsy have 
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been identified in multiple voltage- and ligand-gated ion channels including sodium, calcium 
and potassium channels and nAch and GABAA receptors (Scheffer and Berkovic, 2003). 
Impairment of GABAergic neurotransmission by genetic mutations and/or application of 
GABAA receptor antagonists cause epileptic seizures, whereas drugs enhancing GABAergic 
neurotransmission represent an important class in antiepileptic therapy (Sperk et al., 2004). 
 
4.3.1 MUTATIONS IN GABAA RECEPTOR SUBUNITS ASSOCIATED WITH   
         EPILEPSY 
  
Mutation Epilepsy Functional Consequences References 
γ2K289M GEFS+ Shorter mean open times compared to 
wildtype receptors; reduces protein surface 
expression 
Baulac et al., 
2001; Bianchi 
et al., 2002 
γ2R43Q CAE, febrile 
seizures 
Significant reduction of the peak current 
amplitude; reduced surface expression of 
the receptor protein resulting from a 
receptor retention in the ER 







γ2Q351X GEFS+ Introduces a premature stop codon at 
position Q351; formation of non-functional 
receptors 






CAE, FC Results in a truncated γ2 subunit protein; 
causes non-functional channels 
Macdonald et 
al., 2004 
α1A322D JME Causes reduced peak current amplitudes, 
altered current kinetics and reduced mean 
channel open times; affects α1 subunit 
trafficking after translation; due to the 
misfolding of the protein the mutant subunit 
is degraded in the ER (ERAD) 






GEFS+, JME Reduces current amplitudes and receptor 
surface expression 
 




GEFS+ Generalized epilepsy with febrile seizures plus 
ER Endoplasmatic reticulum 
FC Febrile convulsions 
CAE Childhood absence epilepsy  
JME Juvenile myoclonic epilepsy 
 
4.3.2 TEMPORAL LOBE EPILEPSY 
In patients suffering from temporal lobe epilepsy and animal models profound changes in 
GABAA receptors function have been observed such as a substantial cell loss in CA1 
accompanied by a dramatic loss of GABAA receptors (Sperk et al., 2004; Mohler, 2006). In 
these cells subtype-specific changes in the subcellular distribution with an increase of α1, α2, 
α3 and γ2 were detected pointing to a potential sprouting of GABAergic axons in the epileptic 
dentate gyrus. The latter might represent a compensatory mechanism to the loss of 
GABAergic neurons in the dentate gyrus (Mohler, 2006). Interictal activity in individuals 
suffering from temporal lobe epilepsy is apparently linked to depolarising GABAergic 
synaptic events at pyramidal cells (Cohen et al., 2002). The depolarising GABA-mediated 
response is more likely caused by a very negative resting potential of these cells rather than 
by changes in the chloride gradient (Stein and Nicoll, 2003). This finding is of major 
importance, as approximately 50% of all clinically used antiepileptics owe their efficacy 
either totally or at least partially to potentiation of GABA-mediated responses (Mohler, 2006). 
 
4.3.3 ABSENCE EPILEPSY  
Interconnected networks of inhibitory neurons regulate oscillations throughout the CNS. One 
of these netoworks, the thalamic reticular nucleus (TRN), participates in many thalamo-
cortical oscillations such as spindles in sleep and spike-wave seizures typically observed in 
generalized absence epilepsy. Similar to the generation of sleep spindles, spike-wave seizures 
may result from events, in which TRN neurons inhibit thalamocortical (TC) relay neurons, 
thereby inducing rebound bursts mediated by T-type channels resulting in a reexcitation of the 
TRN. TRN has been shown to be the source of the hyperpolarizing input that recovers 
calcium currents mediated by T-type channels in TC neurons from inactivation, suggesting 
that the TRN contributes to absence seizures.  
The antiabsence drug clonazepam is known to suppress rhythmic activity in thalamic and 
thalamocortical slices. In the TRN, clonazepam acts on α3 containing GABAA receptors as 
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well as in TC neurons on α1 containing receptors, an enhancement which is required to 
suppress oscillations in thalamic slices (Sohal et al., 2003; Mohler, 2006). 
 
4.4 SCHIZOPHRENIA 
A deficiency in GABAergic inhibitory neurotransmission is assumed to contribute 
particularly to the symptoms of schizophrenia (Lewis et al., 2005). Changes in cortical 
GABAergic systems have been reported in post-mortem brains of individuals suffering from 
schizophrenia including reduced uptake and release of GABA and a decreased activity of the 
glutamic acid decarboxylase. The axon terminals of GABAergic chandelier neurons were 
insufficient in the prefrontal cortex as shown by a 40% reduction of GAT-1 (Woo et al., 1998; 
Mohler, 2006). 
Additionally, there is evidence for an enhanced α2-containing receptor expression in the axon 
initial segment of pyramidal cells, pointing to a synapse specific deficit of GABA-mediated 
neurotransmission in schizophrenia (Volk et al., 2002). The ratios of γ2 subunit splice variants 
are apparently affected in the prefrontal cortex of schizophrenics (Huntsman et al., 1998). In 
the primate brain dopamine (D4) receptors regulate GABAergic interneurons in the cerebral 
cortex, hippocampus, thalamic reticular nucleus and globus pallidus. Thus, the beneficial 
effects of clozapine in the treatment of schizophrenia may be partially caused by a D4-
mediated modulation of GABAA receptors (Mrzljak et al., 1996; Mohler, 2006). 
The GABAergic control in the dopaminergic system is mainly mediated via α3- containing 
receptors (Fritschy and Mohler, 1995; Pirker et al., 2000). α3-/- mice display a significant 
deficit in prepulse inhibition of the acoustic startle reflex, underlying the deficit in 
sensorimotor information processing (Yee et al., 2005). After administration of the dopamine 
antagonist haloperidol this deficit was normalised, suggesting that this effect is mainly caused 
by an increased activity of the dopaminergic system (Yee et al., 2005). Compounds 
selectively interacting with α3-containing receptors might be effective agents in treating the 
sensorimotor deficits in various psychatric diseases (Mohler, 2006). 
There is evidence, that the hippocampus plays also an important role in the modulation of 
prepulse inhibition. In a α5H105R point mutated mouse prepulse was diminished 
accompanied by an increase in spontaneous motor activitiy (Hauser et al., 2005). 
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5. GABAB RECEPTORS 
The metabotropic GABAB receptor was first identified based on the receptor's distinct 
pharmacological profile compared to ionotropic GABAA or GABAC receptors (Hill and 
Bowery, 1981).  
Subsequently, it was shown that GABAB receptors are G-protein coupled receptors (GPCR) 
that inhibit the adenylyl cyclase via the Gαi/o subunits of the activated G-protein (Hill, 1985).  
There is evidence that GABAB receptors are involved in regulation of transmitter release at 
several synapses (Bettler and Tiao, 2006). GABAB receptors also regulate Ca2+- and K+-
channels at both pre- and postsynaptic sites via the Gβγ subunits of the G-Protein (Bowery et 
al., 2002, Calver et al., 2002; Bettler et al., 2004). Presynaptic GABAB receptors have been 
found on both inhibitory and excitatory terminals where they act as auto- and heteroreceptors, 
respectively. Upon activation of presynaptic GABAB receptors neurotransmitter release is 
suppressed via inhibition of voltage-gated Ca2+-channels (Mintz & Bean, 1993; Poncer et al., 
1997). Postsynaptic GABAB receptors have been shown to induce slow inhibitory 
postsynaptic currents (sIPSC) by activating Kir3-type K+-channels, which induce a 
hyperpolarization of the membrane, thus postpone excitatory currents (Luscher et al., 1997). 
GABAB receptors modulate synaptic plasticity, heterosynaptic depression, population burst 
firing and inhibition of backpropagating action potentials (Bettler and Tiao, 2006), thus they 
represent promising drug targets (Bettler et al., 2004, Cryan and Kaupmann, 2005; Bowery, 
2006). Several indications are available for the GABAB agonist baclofen. However, the use of 
baclofen in humans is limited due to the rapid development of tolerance and adverse effects 
after systemic administration. Thus, much effort is put in the development of novel 
compounds that might overcome the shortcomings of the so far available GABAB receptor 
agonists (Bettler and Tiao, 2006). 
So far, 2 molecular subtypes of GABAB receptors are established (Bettler et al., 2004, Bettler 
and Tiao, 2006). There is evidence that elusively upon assembly of GABAB1 and GABAB2 
subunits functional GABAB receptors are formed (Marshall et al., 1999, Mohler and Fritschy, 
1999; Bettler et al., 2004). Interaction of GABAB1 with GABAB2 subunits is not only 
obligatory for cell surface expression but also for robust G-protein coupling (Margeta-
Mitrovic et al., 2000, Calver et al., 2001, Galvez et al., 2001). 
The molecular diversity in the GABAB system mainly arises from the GABAB1a and 
GABAB1b subunit isoforms (Kaupmann et al., 1997) and there is also evidence for two 
isoforms for GABAB2 (Bettler and Tiao, 2006). Structurally, they differ in their N-terminal 
domain by a pair of sushi repeats that is present in GABAB1a, but not in GABAB1b (Blein et 
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al., 2004, Bettler and Tiao, 2006). This structural peculiarity -Sushi repeats- is also known as 
complement control protein modules, or short consensus repeats that have been found in other 
GPCR as well, play a role in mediating protein interactions in a wide variety of adhesion 
proteins (Bettler and Tiao, 2006). 
GABAB receptors were the first example of GPCR that inevitably needs to heterodimerize to 
function. This unique property has been employed to study the mechanism underlying subunit 
assembly and receptor surface trafficking. It is well established that a C-terminal arginine-
based ER retention/retrieval signal, RSRR, retains unassembled GABAB1 subunits in the ER 
and limits surface expression to correctly assembled heteromeric receptors (Couve et al., 
1998, Margeta-Mitrovic et al., 2000; Pagano et al., 2001, Bettler and Tiao, 2006). Most likely, 
the RSRR signal in GABAB1 is inactivated by interaction of the GABAB1 with the GABAB2 













Figure 14 Schematic illustration of GABAB receptors as heterodimers of two subunits, GABAB1 (dark 











6. GABAC RECEPTORS, A GABAA  RECEPTOR SUBTYPE 
GABAC receptors gate Cl--currents in various parts of the vertebrate brain. GABAC receptors 
were first described in interneurons of the spinal cord. Later, GABAC receptors were found in 
the retina (Enz and Cutting, 1998). Compared to GABAA receptors, GABAC receptors exhibit 
distinct electrophysiological properties: they are characterized by i.) higher sensitivity for 
GABA, ii.) smaller current amplitudes, iii.) they do not desensitise; iv.) prolonged single 
channel mean open times and v.) a lower chloride conductance (Feigenspan et al., 1993). 
GABAC receptors differ from GABAA and GABAB receptors in regard to their 
pharmacological properties. They are insensitive for typical GABAA receptor modulators such 
as benzodiazepines and barbiturates, and they are not blocked by bicuculline and they cannot 
be activated by the GABAB agonist baclofen (Bormann and Feigenspan, 1995). 
It was, however, suggested to classify GABAC receptors as GABAA receptor subtype 
(Barnard et al., 1998; Olsen and Sieghart, 2008; Collingridge et al., 2008) 
These receptors are composed of ρ subunits. A major characteristic of ρ subunits is their 
ability to build functional homooligomers (Enz and Cutting, 1998). Upon homooligomeric 
expression of ρ2 subunits GABA-gated channels are formed, however, with markedly lower 
whole cell currents produced compared to ρ1 receptors (10-100pA for ρ2 versus 200-1000pA 
for ρ1) (Wang et al., 1994). The ρ3 as well as the white perch ρ subunit have been also 
demonstrated to form homooligomeric, functional GABA-gated channels with 
electrophysiological and pharmacological properties similar to that of native GABAC 
receptors (Enz and Cutting, 1998). Human ρ1 subunits apparently do not assemble with 
GABAA receptor α1, β1, γ2 and glycine receptor β subunits (Shimada et al., 1992). Besides 
electrophysiological and biochemical evidence, there is moreover anatomical data showing 
that GABAC receptor subunits do not interact with GABAA or glycine receptor subunits 
(Koulen et al., 1998). 
GABAC receptors are sensitive to picrotoxinin (Enz and Cutting, 1998). In addition to the 
non-competitive inhibition of GABAC receptors by pore occlusion, picrotoxinin has been 
shown to display a competitive antagonism on GABAC receptors. Mutation P309S in the 
channel lining region enhances picrotoxinin sensitivity (Wang et al., 1995). A similar residue 
V257 in the GABAA receptor M2 domain is close to the picrotoxinin binding site or even 





















Figure 15 The agonist/antagonist binding site of GABAC receptors. In analogy to GABAA receptors 
the binding site is constituted by different loops (A-E) with amino acid contributing to the binding 
pocket. However, loop F in ρ1 homomeric GABAC receptor is apparently not involved in agonist 
binding which stands in clear contrast to GABAA receptors (see also chapter 1.5.). Residues Asp136, 
Phe138, and Val140 in loop A (depicted in red), Tyr198 and Tyr200 in loop B (depicted in cyan), and 
Tyr241, Thr244, and Tyr247 in loop C (depicted in green) are assumed to form the principal site of the 
binding pocket, whereas residues Tyr102 and Arg104 in loop D (depicted in yellow) and Val155, 
Met156, Val159, Ser168, and Arg170 in loop E (depicted in purple) form the complimentary face of 
the binding pocket (Sedelnikova et al., 2006). 
 
7. MODULATION OF GABAA RECEPTORS BY PLANT  
    EXTRACTS AND NATURAL PRODUCTS 
7.1 VALERIAN (VALERIANA OFFICINALIS) 
Valerian root (Valeriana officinalis L.) is a traditionally used herbal drug with sedative and 
CNS depressant effects (Houghton, 1999). Its mechanism of action, however, is not known so 
far and its efficacy is discussed controversially (Bent et al., 2006; Trauner et al., 2008).  
In order to get insight into the molecular mechanism of action and target of Valerian 
preparations and active constituents of Valerian, respectively, multiple investigations on 
different molecular targets including the GABAergic system (Santos et al., 1994; Cavadas et 
al., 1995; Ortiz et al., 1999; Yuan et al., 2004) or Adenosine type 1 (A1) receptors 
(Schumacher et al., 2002) have been carried out (Trauner et al., 2008). Aqueous Valerian 
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extracts have been shown to enhance [3H] GABA release due to a reversal of the GABA 
carrier (Santos et al., 1994). Cavadas et al. (1995) observed a displacement of [3H] muscimol 
by aqueous and hydroalcoholic extracts of Valerian. Ethanolic Valerian extracts enhanced 
[3H] flunitrazepam binding (Ortiz et al., 1999). Various flavonoids including 6-
methylapigenin, 2S(-)-hesperidin and linarin displayed sleep-enhancing, sedative and 
anxiolytic properties in animal models (Marder et al., 2003; Fernandez et al., 2004). 
Previously, a Valerian extract and valerenic acid were shown to decrease the firing rate in 
brainstem neurons in a concentration dependent manner, an effect that could be antagonized 
by bicuculline (Yuan et al., 2004). In a previous study, valerenic acid was identified as a 
modulator of GABAA receptors containing β2 or β3 subunits (Khom et al., 2007; see chapters 
results and discussion). Benke et al. (2008) provided evidence for an in-vivo interaction of 
valerenic acid and valerenol with GABAA receptors. Both compounds displayed anxiolytic 
activity with high potencies in mice. In mice carrying the point mutation β3N265M valerenic 
acid failed to show anxiolytic effects. It has thus been suggested that neurons expressing β3 
containing GABAA receptors represent a major cellular substrate for the anxiolytic action of 
valerenic acid (Benke et al., 2008). 
 
7.2 BLACK COHOSH (ACTAEA RACEMOSA) 
Preparations of Black Cohosh (Actaea racemosa) represent popular and frequently applied 
herbal products in the treatment of postmenopausal disorders; there is arising evidence from 
clinical trials that Actaea racemosa preparations containing actein affect CNS related 
symptoms of postmenopausal disorders including insomnia, restlessness and anxiety. The 
estrogenic effect of actein and Black Cohosh preparations remains controversially discussed 
(Cheema et al., 2007; McBane, 2008, Uebelhack et al., 2006). 
There is accumulating evidence that Black Cohosh preparations are more effective than 
placebo in alleviating moderate vasomotor symptoms associated in the menopause (Cheema 
et al., 2007; McBane, 2008, Uebelhack et al., 2006). In particular, an improvement in sleep 
and mood disturbances was observed (Cheema et al., 2008). 
Interactions with CNS targets of Black Cohosh and its main constituents have been suggested, 
including the central endogenous opioid system (Reame et al., 2008), the µ-opoid receptor 
(Rhyu et al., 2006), 5-HT1A, 5-HT1D and 5-HT7 receptors (Burdette et al., 2003) or D2 
receptors (Jarry et al., 2003). 
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8. AIMS 
Valerian and Black Cohosh are traditionally used as “phytopharmaceuticals” to treat insomnia 
and anxiety (Valerian) and postmenopausal disorders (Black Cohosh) including symptoms 
like restlessness and agitation. In order to analyse the basis of the suggested sedative and 
anxiolytic effects I studied the action of the extracts and some of their main constituents on 
GABAA receptors expressed in Xenopus oocytes under two-microelectrode voltage clamp.  
Specific aims were: 
1. To analyse the modulation of GABAA receptors by commercially available 
Valerian extracts. 
2. To characterise the action of valerenic acid, acetoxy- and hydroxy-valerenic 
acid (natural compounds isolated from Valerian) on GABAA receptors. 
3. To characterise the subunit-specific action of valerenic acid on GABAA 
receptors.  
4. To study the modulation of GABAA receptors by Black Cohosh extracts.  
5. To analyse the molecular mechanism of action of actein, a compound isolated 
from Black Cohosh, on GABAA receptors. 
6. To investigate a possible subunit-specific action of actein 
7. To study the in vivo action of actein in a mouse model (Open Field, Elevated 
Plus Maze, Light Dark Choice, Stress induced hyperthermia) 
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9. MATERIALS AND METHODS 
 
9.1 CHEMICALS 
Valerenic acid was from Extrasynthese, France, Lyon, acetoxy-valerenic acid from LGC 
Promochem, Germany, Wesel and hydroxy-valerenic acid was isolated from Valerian root 
(kindly provided by Univ. Prof. DDr. Brigitte Kopp). A first sample of actein was kindly 
provided by Univ. Prof. DDr. Brigitte Kopp. Actein was also obtained from LGC 
Promochem, Germany, Wesel and Herbstandard Inc., California, USA. The structural formula 
for valerenic acid, acetoxy- and hydroxy-valerenic acid and actein, respectively, are given in 
Fig. 18 and 26. Valerian Extracts C1, C2, C3, C4 and C5 and Actaea racemosa extracts A1, 
A2 and A3 were kindly provided by Univ.Prof. DDr. Brigitte Kopp and colleagues (Mag. 
Gabriele Trauner and Mag.Ulrike Jäger). Stock solutions (100 mM) were prepared in DMSO 
(Dimethyl Sulfoxide, Sigma, Austria). Because of low solubility in ND96, valerenic acid, the 
two derivatives and actein were only used up to a concentration of 300 µM. Equal amounts of 
DMSO were present in control and compound-containing solutions. The maximum DMSO 
concentration in the bath (0.3%) did not affect IGABA (Khom et al., 2006; Khom et al., 2007). 
For experiments on mice, a stock solution of actein was prepared in 100% DMSO (50mg 
Actein/375 µl DMSO). Actein was further diluted in 0.9% sodiumchloride solution up to the 
final desired concentrations. Actein and control solutions were freshly prepared every day 
prior to experiments. Care was taken for equal amounts of DMSO in the actein and control 
solutions (Khom et al., in preperation). 
 
9.2 ANIMALS 
Male mice (C57Bl/6N) were obtained from Charles River Laboratories (Germany). For 
breeding and maintenance mice were group housed with free access to food and water. 
Temperature was fixed to 23±1°C and 60% humidity with a 12 h light–dark cycle (lights on 
0700–1900 hours). Male mice at 3–8 months age were tested in all experiments. All 
procedures involving animals were approved by the Austrian Animal Experimentation Ethics 
Board in compliance with the European convention for the protection of vertebrate animals 
used for experimental and other scientific purposes ETS no.: 123. Every effort was taken to 





9.3 EXPRESSION AND FUNCTIONAL CHARACTERIZATION OF GABAA  
       RECEPTORS  
Preparation of stage V-VI oocytes from Xenopus laevis, synthesis of capped off run-off 
poly(A+) cRNA transcripts from linearized cDNA templates (pCMV vector) was performed 
as described (Khom et al. 2006). Briefly, female Xenopus laevis (NASCO, USA) were 
anaesthetised by exposing them for 15 minutes to a 0.2 % solution of MS-222 (methane 
sulfonate salt of 3-aminobenzoic acid ethyl ester; Sandoz) before surgically removing parts of 
the ovaries. Follicle membranes from isolated oocytes were enzymatically digested with 2 
mg/ml collagenase (Type 1A, Sigma). One day after isolation, the oocytes were injected with 
about 10-50 nl of DEPC- treated water (diethyl pyrocarbonate, Sigma, Germany) containing 
the different cRNAs at a concentration of approximately 150 - 3000 ng/µl/subunit. The 
amount of cRNA was determined by means of a NanoDrop ND-1000 (Kisker-biotech, 
Steinfurt, Germany).  
Mutation β1S290N was introduced by the “gene SOEing” technique (Horton et al., 1989). This 
involved synthesizing mutagenic oligonucleotides to introduce the desired mutation, and 
using a silent restriction site was used to screen for the mutation. The mutant cDNA was 
verified by sequencing.  
To ensure expression of the gamma-subunit in the case of α1β2γ1, α1β2γ2S, α2β2γ2S, α2β2γ1 and 
α6β2γ2S  receptors, cRNAs were mixed in a ratio of 1:1:10 (Boileau et al., 2002b) except 
α4β2γ2S (ratio 3:1:5). For receptors comprising only α and β subunits (α1β2, α2β2, α1β3, 
α1β2N265S (cDNA gift of E. Sigel), α2β2, α3β2, α5β2), the cRNAs were mixed in a ratio 1:1. 
cRNAs for of α1β1 and α1β1S290N channels were injected in a ratio 3:1 to avoid formation of β1 
homooligomeric GABAA receptors (Krishek et al., 1996). Oocytes were stored at 18°C in 
ND96 solution (Methfessel et al., 1986). Electrophysiological experiments were done using 
the two-microelectrode voltage-clamp method at a holding potential of −70 mV making use 
of a TURBO TEC 01C amplifier (npi electronic, Tamm, Germany) and an Axon Digidata 
1322A interface (Molecular Devices, Sunnyvale, CA). Using pCLAMP v.9.2 data acquisition 
was carried out. The bath solution contained 90 mM NaCl, 1 mM KCl, 1 mM MgCl2⋅6H2O, 1 
mM CaCl2 and 5 mM HEPES (pH 7.4). Microelectrodes were filled with 2M KCl and had 






9.4 PERFUSION SYSTEM 
GABA and VA and GABA and actein, respectively were applied by means of fast perfusion 
system (see Baburin et al., 2006 for details; Khom et al., 2006). Drug or control solutions 
were applied by means of a TECAN Miniprep 60 permitting automation of the experiments. 
To elicit IGABA the chamber was perfused with 120 µl of GABA-containing solution at volume 
rate between 300 and 1000 µl/s. The IGABA rise time ranged between 100 and 250 ms (see 
Khom et al., 2006). Care was taken to account for possible slow recovery from increasing 
levels of desensitization in the presence of high GABA, valerenic acid and actein 
concentrations. The duration of washout periods was therefore extended from 1.5 minutes (1-
20 µM GABA, <10 µM valerenic acid or actein) to 30 minutes (≥100 µM GABA, ≥10 µM 
valerenic acid and actein) respectively. Oocytes with maximal current amplitudes >3 µA were 
discarded to exclude voltage-clamp errors (Khom et al., 2006; Baburin et al., 2006; Khom et 













Figure 16 Cross-section view of the oocyte perfusion chamber. Two microelectrodes (M1 and M2) 
are inserted into the angular access inlets in a glass plate (the inlets serve simultaneously as perfusion 
holes) covering the small (15 µl) oocyte chamber. Drugs and control solutions were applied by a 
Tecan Miniprep 60 application tube (AT) to a quartz funnel surrounding the microelectrode access 
holes (MAH). Residual solution was removed from the funnel before drug application via the funnel 







9.5 ANALYZING CONCENTRATION-RESPONSE CURVES 
Stimulation of chloride currents by modulators of the GABAA receptor was measured at a 
GABA concentration eliciting between 5 and 10% of the maximal current amplitude (EC5–10). 
The EC5-10 was determined at the beginning of each experiment.  
Enhancement of the chloride current was defined as (I(GABA+Comp)/IGABA) – 1, where 
I(GABA+Comp) is the current response in the presence of a given compound (valerenic acid or 
actein)  and IGABA is the control GABA current. To measure the sensitivity of the GABAA 
receptor for a given compound, it was applied for an equilibration period of 1 minute before 
applying GABA (EC5-10). Concentration-response curves were generated and the data were 
fitted by non-linear regression analysis using Origin software (OriginLab Corporation, USA). 









, where nH is the Hill coefficient. Each data 
point represents the mean ± S.E. from at least 4 oocytes and ≥ 2 oocyte batches. Statistical 
significance was calculated using paired Student t-test with a confidence interval of p < 0.05 
(Khom et al., 2007). 
 
 
9.6 OPEN FIELD TEST 
The open field test was performed as previously described by Wittmann et al. (2008). Briefly, 
the animals’ behaviour was tested over 10 min in a 50x50 cm flexfield box equipped with 
infrared rearing detection. Illumination was set to 150 lux. Animals were video monitored and 
their explorative behavior was analyzed using the Video-Mot 2 equipment and software 
(TSE-systems, Bad Homburg, Germany). Arenas were subdivided into border (up to 8 cm 
from wall), center (20x20 cm, i.e. 16% of total area), and intermediate area according to the 
recommendations of EMPRESS (European Mouse Phenotyping Resource of Standardised 
Screens; http://empress.har.mrc.ac.uk) (Wittmann et al., 2008).  
 
 
9.7 ELEVATED PLUS MAZE TEST 
The elevated plus maze test was performed as previously described (Wittmann et al., 2008).  
The animals’s behavior was tested over 5 min on an elevated plus maze 1m above ground 
consisting of two closed and two open arms, each 50x5 cm in size. The test instrument was 
built from gray PVC; the height of closed arm walls was 20 cm. Illumination was set to 180 
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lux. Animals were placed in the center, facing an open arm. Analysis of open and closed arm 
entries and time on open arm was automatically done with Video-Mot 2 equipment and 
software (Wittmann et al., 2008). 
 
9.8 LIGHT-DARK CHOICE TEST 
The light-dark choice test was adopted and performed as previously described by Wittmann et 
al. (2008). Explorative behavior in a brightly lit area (400 lux) was investigated by insertion 
of a black box into the open field arena, covering one third of the space. Time spent and 
distance travelled was measured over a 10 min period in the open area. One small field 
directly at the entrance to the black box was assigned as transition zone. To reach the larger 
compartment assigned as open area, the mouse had to leave the dark area completely 
(Wittmann et al., 2008). 
 
9.9 STRESS-INDUCED HYPERTHERMIA TEST 
The stress-induced hyperthermia (SIH) test was performed as previously described (Wittmann 
et al., 2008). A temperature probe, lubricated with glycerol, was inserted into the rectum of 
the mouse for a depth of up to 2 cm. The temperature probe remained in the animal till a 
stable temperature was reached (maximum 10 s). Temperature measurement was repeated 
after 10 min and the rise in temperature between the first and second measurement was 
considered as stress-induced hyperthermia (Olivier et al., 2003). 
 
9.10 HOME CAGE ACTIVITY 
Basal activity and circadian rhythm of control and actein-treated mice was monitored in their 
home cages using the Infra-Mot system (TSE, Bad Homburg, Germany). Animals were 
observed for two dark–light cycles after an initial accommodation phase of several hours 
(Wittman et al., 2008). 
 
 
9.11 STATISTICAL ANALYSIS OF BEHAVIORAL EXPERIMENTS 
For comparison of control groups and actein-treated groups the Student’s t-test was used. 
Comparison of more than two groups was done by one-way ANOVA, applying GraphPad 
Prism 4.0 software. P-values of < 0.05 were accepted as statistically significant. All data are 
given as mean ± SEM (n). 
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10. RESULTS 
The effects of Valerian and Black Cohosh extracts and selected natural products from these 
plants on GABAA receptor function were investigated. For this purpose, GABAA receptors 
comprising different subunit compositions were expressed in Xenopus oocytes and the 
modulation of GABA-induced currents (IGABA) investigated by means of the 2-microelectrode 
voltage clamp technique (TEVC) and a fast perfusion system. To analyse the potentially 
sedative, hypnotic and anxiolytic effects of actein in vivo the Open-field-, the Dark-Light 
Choice, the Elevated Plus Maze- and Stress-Induced-Hyperthermia test were applied. 
 
10.1 VALERENIC ACID POTENTIATES AND INHIBITS GABAA RECEPTORS: 
MOLECULAR MECHANISM AND SUBUNIT SPECIFITY 
 
10.1.1 MODULATION OF IGABA BY VALERIAN EXTRACTS 
The modulation of IGABA by commercially available Valerian extracts (kindly provided by 
Univ. Prof. DDr. Brigitte Kopp and colleagues) was investigated on recombinant GABAA 
receptors (α1β2γ2S) expressed in Xenopus laevis oocytes. As illustrated in Fig. 17, the extracts 
at a concentration of 100 µg/ml significantly stimulated (p<0.05) IGABA. The strongest effect 
was observed for extracts C3 and C4, enhancing IGABA by 133.9 ± 15.9% (n=6) and 123.4 ± 
21.0% (n=6), respectively. The effect was less pronounced for the extracts C1 (39.7 ± 8.8 %, 












Figure 17 Modulation of IGABA through GABAA receptors composed of α1β2γ2S-subunits by Valerian 
extracts of different polarity at a concentration of 100 µg/ml. Each value represents the mean ± S.E. 
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from at least 4 oocytes and ≥ 2 oocyte batches. (*) indicates significantly different from zero (p < 
0.05). 
 
10.1.2 POTENTIATION OF IGABA BY VALERENIC ACID THROUGH α1β2, α1β2γ1 
AND α1β2γ2S CHANNELS 
The modulation of IGABA by VA was investigated on recombinant GABAA receptors 
expressed in Xenopus laevis oocytes. Modulation of IGABA by valerenic acid was first studied 
on GABAA channels composed of either α1β2 or α1β2γ1/2S subunits. As shown in Fig. 19 A, B 
valerenic acid exhibited a positive allosteric modulatory effect at concentrations ≥1 µM by 
enhancing IGABA. The effect was dose-dependent and the averaged concentration-response 
curve shows that maximum stimulation of α1β2γ2S receptors occurred at ∼100 µM (Fig. 19 B). 
The maximal potentiation of IGABA (efficiency) through α1β2γ1 (235.6 ± 46.4%, n=8) and 
α1β2γ2S channels (400.0 ± 77.6 %, n=12) was however not significantly higher than in 
channels composed of α1 and β2 subunits (245.7 ± 53.3 %, n=17) (see Fig. 19 A and B, Tables 
1 and 2). At concentrations ≥30 µM a direct activation of GABAA channels by valerenic acid 
was observed. This finding is illustrated in the inset of Fig. 18 A (see Fig. 23 for detailed 
analysis of channel activation by valerenic acid). At concentrations ≥100 µM current 
enhancement by valerenic acid was less pronounced or even inhibition of control IGABA was 
















Figure 18: (A) Structure of valerenic acid and derivatives (B) chemical structure of loreclezole (Khom 
et al., 2007) 
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10.1.3 POTENTIATION OF IGABA BY VALERENIC ACID THROUGH α2β2,  
            α3β2, α4β2γ2S, α5β2, α2β2γ1 AND α2β2γ2S CHANNELS 
A possible α-subunit specificity was analysed by substituting the α1 by α2, α3, α4 and α5 
subunits and subsequent analysis of the modulation of IGABA through the corresponding 
GABAA channels. A comparison of Fig. 19 B and C reveals a very similar modulation of 
GABAA receptors incorporating α2 instead of α1 subunits. As illustrated in Fig. 19 B and C a 
slightly higher efficiency of valerenic acid in γ2S-containing receptors was observed (see 
Table 1 for fitted efficiencies and EC50s). A reliable estimation of the EC50 values and 
maximal IGABA stimulation was complicated by an apparent IGABA inhibition at concentrations 
≥100 µM that was consistently observed for all subunit compositions (except for α2β2γ1 
receptors). The bell-shaped concentration-effect curves might reflect a low-affinity open-
channel block at high valerenic acid concentrations (see Fig. 24). Maximal stimulation of 
IGABA through GABAA receptors composed of α3β2 and α5β2 subunits was comparable to α2β2 
or α1β2 receptors (see Table 1 for efficiencies and EC50 values, compare Fig.19 B, C and D 
and Table 2). Interestingly, α4β2γ2S receptors displayed a significantly lower sensitivity for 








































Figure 19 (A) Typical IGABA recordings illustrating concentration-dependent modulation by VA of 
GABA elicited chloride currents through α1β2γ2S-containing receptors. Direct activation of GABAA 
receptors during preincubation with 30 µM VA is shown in an inset. Concentration-effect curves for 
action of VA on (B): α1β2 (●), α1β2γ1 (▲) and α1β2γ2S (■), (C): α2β2 (●), α2β2γ1 (▲) and α2β2γ2S (■) 
and (D): α3β2 (●), α4β2γ2S (▲) and α5β2 (■) receptors using an GABA EC5-10 (EC50 and nH values are 
given in Table 1). Data points represent means ± S.E. from at least 4 oocytes from ≥ 2 batches. IGABA 
at 100 and 300µM (α1β2) and at 300 µM (α1β2γ2S and α1β2γ1) (Fig. B) (grey symbols), IGABA at 100 
and 300 µM (α2β2) and at 300 µM (α2β2γ2S) (Fig. C) (grey symbols) and IGABA at 100 µM and 300 µM 
















Number (n) of 
experiments 
 
α1β2 5.2 ± 2.4 245.7 ± 53.3 1.5 ± 0.4 n = 5 
α1β3 16.6 ± 3.8 487.3 ± 78.9 1.7 ± 0.3 n = 5 
α1β2γ1 18.0 ± 7.1 235.6 ± 46.4 1.3 ± 0.2 n = 4 
α1β2γ2S 13.6 ± 4.1 400.0 ± 77.6 1.5 ± 0.3 n = 4 
α2β2 7.2 ± 2.6 187.4 ± 36.8 1.8 ± 0.6 n = 5 
α2β2γ1 16.8 ± 6.4 280.5 ± 36.1 1.0 ± 0.2 n = 4 
α2β2γ2S 11.3 ± 1.6 421.4 ± 26.3 1.5 ± 0.1 n = 4 
α3β2 13.2 ± 10.5 188.5 ± 90.4 1.4 ± 0.5 n = 5 
α5β2 7.8 ± 6.1 174.2 ± 57.0 1.7 ± 1.1 n = 4 
α4β2γ2S 2.3 ± 4.6  69.0 ± 23.6 1.5 ± 1.6 n = 4 
α1β1S290N 10.4 ± 3.8 371.3 ± 69.6 1.5 ± 0.3 n = 4 
 




Table 2 Comparison of efficiencies (upper-right) and potencies (lower-left) for GABAA receptors of 
different subunit compositions. (*) indicates statistically significant (p<0.05) differences. 
         IMAX 
EC50 α1β2 α1β3 α1β2γ1 α1β2γ2S α2β2 α2β2γ1 α2β2γ2S α3β2 α5β2 α4β2γ2S α1β1S290Ν 
α1β2  *     *   *  
α1β3 *  *  * *  * * *  
α1β2γ1       *   *  
α1β2γ2S     *    * *  
α2β2  *     *   * * 
α2β2γ1       *   *  
α2β2γ2S *       * * *  
α3β2            
α5β2           * 
α4β2γ2S  * * *  * *    * 
α1β1S290Ν            
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    10.1.4 MODULATION OF IGABA BY VALERENIC ACID AT DIFFERENT  
                        GABA CONCENTRATIONS 
In order to gain insight into the mechanism of IGABA modulation by valerenic acid, GABA 
concentration-response curves in the presence and absence of valerenic acid on α1β3 channels 
were compared. Valerenic acid was applied in a concentration of 30 µM to minimise a 
potential inhibition of IGABA (see Fig. 19 B, C and D). At this concentration valerenic acid 
shifted the concentration-effect curve towards lower GABA concentrations and also slightly 


















Figure 20 GABA concentration-effect curve of α1β3 GABAA receptors (control, ■) and in the presence 
of 30 µM VA (●). Corresponding EC50-values were 5.3 ±0.6 µM (nH= 1.1 ± 0.1, n=4) for control and 
1.7 µM ± 0.7 µM (nH =0 .7 ± 0.2, n=4) in the presence of VA, respectively. The increase in the 
maximal IGABA may result from a direct activation of GABAA receptors (see Fig. 23). Data points 
represent means ± S.E. from at least 4 oocytes from ≥ 2 batches (Khom et al., 2007). 
 
      10.1.5 VALERENIC ACID DOES NOT INTERACT WITH THE BZD SITE 
Valerenic acid has a strong stimulatory effect on GABAA channels not containing γ subunits. 
A trend towards a slightly higher efficiency of valerenic acid on α1/2β2 receptors containing a 
γ2S subunit (Fig. 19 B-D), however, suggested a possible interaction of valerenic acid with the 
benzodiazepine binding pocket. To investigate this, IGABA through α1β2γ2 receptors was 
stimulated with 5 µM valerenic acid either in the absence or presence of 1 µM of the 
benzodiazepine antagonist flumazenil. Flumazenil did not affect IGABA potentiation 
significantly (77.4 ± 2.3 %, n=3 control vs. 77.3 ± 8.6%, n=3) (Fig. 21 A, B). Moreover, 
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additive effects of valerenic acid and 300 nM diazepam on α1β2γ2S receptors also suggest that 
the binding sites of valerenic acid and the BZD like diazepam are independent of each other 


















Figure 21 (A) Stimulation of IGABA by 5 µM VA is not inhibited by flumazenil. The left bar shows the 
positive allosteric modulation of the GABA (EC5-10)-induced chloride current by 5 µM VA through 
α1β2γ2S receptors. The right bar illustrates that flumazenil (1 µM) does not antagonize VA-induced 
enhancement of IGABA. (B) Typical IGABA through α1β2γ2S receptors in the absence and presence of the 
indicated concentrations of VA or VA and flumazenil, respectively. (C) Additive effects of VA 10 µM 
and diazepam 300 nM. The left bar illustrates the enhancement of IGABA by 10 µM VA, the bar in the 
middle by 300 nM diazepam, whereas the right bar illustrates the enhancement of IGABA under 
coapplication of VA 10 µM and diazepam 300 nM through receptors composed of α1, β2 and γ2S 
subunits. (D) Representative currents through α1β2γ2S channels for the additive effects of VA and 
diazepam (Khom et al., 2007). 
 
     10.1.6 β-SUBUNIT DEPENDENCE OF GABAA RECEPTOR POTENTIATION   
                        BY VALERENIC ACID 
A strong dependence of the modulatory effect of valerenic acid on the β-subunit composition 
of the receptor was observed. Fig. 22 illustrates the effect of valerenic acid on IGABA through 
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GABAA channels with different β-subunit isoforms (channels without γ-subunits). As 
illustrated in Fig. 22 only channels incorporating β2 or β3 subunits were stimulated by 
valerenic acid at concentrations between 1 and 30 µM. The highest efficiency of valerenic 
acid was observed for α1β3 channels. Replacing β2/3 by β1 drastically reduced the sensitivity 
of the resulting GABAA channels. As shown in Fig. 22 A, the stimulation of IGABA through 
α1β1 receptors was almost absent. Interestingly, the point mutation β2N265S (known to reduce 
stimulatory effects by loreclezole, Wingrove et al., 1994) almost completely abolished the 
stimulatory effect of valerenic acid. The corresponding mutation in β1 (β1S290N), however, 
induced sensitivity for valerenic acid. These findings suggest an involvement of this residue 
in either binding of valerenic acid or transduction of the effect. Corresponding representative 
IGABA in absence and presence of 10 µM valerenic acid are shown in Fig. 22 B. The structures 
of valerenic acid, acetoxy- valerenic acid, hydroxy- valerenic acid and loreclezole are 
























































Figure 22 (A) Concentration-dependent effect for VA on α1β1, α1β3, α1β2, α1β2N265S and α1β1S290N 
receptors using a GABA EC5-10. (B) Typical traces for modulation of chloride currents through α1β1, 
α1β3, α1β2, α1β2N265S and α1β1S290N channels by 10µM valerenic acid at GABA EC5-10. Control currents 
(GABA, single bar) and corresponding currents elicited by coapplication of GABA and the indicated 





      10.1.7 DIRECT ACTIVATION OF GABAA RECEPTORS BY VALERENIC  
                        ACID 
As shown in Fig. 19 A, valerenic acid induced currents through GABAA receptors (IVA). Fig. 
23 A illustrates valerenic acid-evoked currents through channels composed of α1 and β2 
subunits. A comparison with the kinetics of an IGABA at low GABA concentrations revealed a 
significantly slower activation of IVA (Fig. 23 A). Compared to a mean current rise time (t10-
90%) of IGABA at EC10 (180 ± 45 ms, n=7) a significantly slower activation of IVA with mean t10-
90% of 680 ± 50 ms (n=5) at valerenic acid concentrations between 30 to 300 µM was 
oberserved. Interestingly, not only the activation of GABAA channels but also the 
deactivation rate of IVA were remarkably slower compared to IGABA. The mean time-constants 
of IVA deactivation of 2083 ± 232 ms (n=5 at 30 - 300 µM VA) were about 10 times larger 
compared to IGABA decay upon washout (200 ± 10 ms, GABA EC10, n=7, Fig. 23 A). With 
higher valerenic acid concentrations, a “wash-off” current (WOC) was observed during rapid 
perfusion of the oocytes with control solution (see Fig. 23 A and C). This finding suggests 
rapid unbinding of valerenic acid from a (low affinity) binding site located in the open 
channel pore (compare with Akk and Steinbach, 2000; Feng et al., 2004). The amplitude of 
the “wash-off” current increased with increasing valerenic acid concentration from 30 to 300 















































Figure 23  
(A) Representative currents illustrating direct activation of GABAA receptors (α1β2) by VA at the 
indicated concentrations in comparison to a GABA-induced current at EC10. (B) Inhibition of IVA (300 
µM) by bicuculline. The left bar illustrates the percentage of the VA-induced current (300 µM) in 
relation to the maximal IGABA at 1mM. The right bar shows the effect of VA in the presence of 5 µM 
bicuculline. (*) indicates statistically significant differences from zero (p < 0.05). 
(C) Estimation of the relative “wash-off” current (WOC) in percentage of corresponding IVA at the 
indicated VA concentrations (Khom et al., 2007). 
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      10.1.8 EVIDENCE FOR OPEN CHANNEL BLOCK BY VALERENIC ACID  
 AND ACETOXY- VALERENIC ACID 
The data shown in Fig. 23 suggest an open channel block mechanism for valerenic acid. This 
hypothesis is supported by the observed “wash-off” currents that increased at high valerenic 
acid concentrations (Fig. 23). Interestingly, acetoxy- valerenic acid induced no stimulation at 
concentrations up to 100 µM (and did not evoke currents when applied at this concentration 
alone, data not shown) but accelerated the current decay through α1β3 channels (Fig. 24 A). 
Making use of these properties (no stimulation but acceleration of current decay) inhibition of 
IGABA in more detail could be studied. The shape of IGABA in the presence of 100 and 300 µM 
acetoxy- valerenic acid revealed a concentration dependent acceleration of the current decay 
(Fig. 24 B), which would agree with an open-channel block. Interestingly, only acetoxy- but 
not hydroxy- valerenic acid accelerated the IGABA decay (data not shown). Plotting the 
reciprocal of the time constants of the acetoxy- valerenic acid induced current decay against 
concentration enabled the estimation of an apparent IC50 value (~190 µM) for an apparent 
open channel block mechanism. A simulation of the bell-shaped concentration-response curve 
of valerenic acid action on α1β3 channels assuming a low affinity open channel block 






















































Figure 24 (A) Concentration-dependent effects for acetoxy-VA (♦), hydroxy-VA (■) on the 
enhancement of IGABA (EC5-10) through α1β3 channels. Broken line illustrates the enhancement of IGABA 
by VA (taken from Fig. 22 A). (B) Representative traces illustrating GABA-induced chloride currents 
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through α1β3 receptors in the absence (control) and the presence of 30 µM, 100 µM and 300 µM 
acetoxy-VA. In the presence of 30, 100 and 300 µM acetoxy-VA IGABA decayed with time constants of 
10.9 ± 0.4 s, 7.4 ± 0.5 s and 5.0 ± 0.2 s. (C) Reciprocals of time constants of acetoxy-VA induced 
IGABA decay plotted as function of the acetoxy-VA concentration. The regression line yields a y-
intercept (rate constant of dissociation from the open channel, k
-
= 0.08 s-1) and a slope (rate constant 
of association with the open channel, k+= 420 s-1M-1) suggesting an IC50 for open channel block of 












Figure 25 (A) Simulated shift of the concentration-response dependency making use of the 
experimental data (EC50s and nH taken from the concentration-effect curves shown in Fig. 19). The 
broken and straight lines illustrate the curves in the presence and absence of 30 µM VA, respectively. 
Direct activation of GABAA receptors by VA was not taken into account. (B) Simulation of 
concentration-dependent enhancement and inhibition of IGABA by VA (in %). Solid line represents a 
simulation of the positive allosteric modulation by VA (EC50 = 15 µM, nH = 1.8) and open channel 
block (IC50 = 190 µM, nH = 1.8). Broken line illustrates the simulated concentration-effect curve 
without open channel block. The approximated IC50 for apparent open channel block of GABAA 













10.2 ACTEIN- A NOVEL HIGHLY EFFICIENT MODULATOR OF GABAA  









Figure 26 Chemical structure of Actein 
      
10.2.1 MODULATION OF IGABA BY ACTAEA RACEMOSA EXTRACTS 
The modulation of IGABA by Acteae racemosa extracts CR-I, CR-II and CR-III (kindly 
provided by Univ. Prof. DDr. Brigitte Kopp and colleagues) was investigated. As illustrated 
in Fig. 27, CR-I, CR-II and CR-III at a concentration of 100 µg/ml significantly (p < 0.05) 
enhanced IGABA. CR-II and CR-III exhibited a stronger modulation of GABA-mediated 
currents, enhancing IGABA by 130.2 ± 14.4% (n=3) and 132.8 ± 33.1% (n=3) compared to the 












Figure 27 Enhancement of IGABA by Actaea racemosa extracts through GABAA channels comprising 
α1β2γ2S subunits at a concentration of 100 µg/ml at GABA EC5-10. Each bar represents the mean ± S.E. 
from at least 3 oocytes and ≥ 2 oocyte batches. (*) indicates significantly different from zero (p < 0.05, 
t-test by ANOVA) 
 
72 
10.2.2 POTENTIATION OF IGABA BY ACTEIN THROUGH GABAA  
                       CHANNELS COMPOSED OF α1, β2 AND γ2S SUBUNITS 
The effects of actein, a major constituent of Actaea racemosa, were examined on GABAA 
receptors heterologously expressed in Xenopus laevis oocytes. Modulation of IGABA by actein 
was first studied on GABAA channels composed of α1β2γ2S subunits. As shown in Fig. 28 A, 
actein exhibited a positive allosteric modulatory effect at concentrations ≥1 µM by enhancing 
IGABA at a GABA EC5-10. The effect was concentration-dependent (n=8) and the averaged 
concentration-response curve shows that maximum stimulation of α1β2γ2S receptors occurred 
at ∼300 µM (Fig. 28 A) and yielded 1091.2 ± 124.6% potentiation of IGABA (see also Table 3). 
The modulatory action of actein at 100 µM was not blocked by flumazenil 1 µM (n=3, data 
not shown). IGABA modulation was not dependent on the presence of a γ subunit. The 
modulation of GABAA channels composed of α1 and β2 subunits (n= 9) was slightly more 
pronounced compared to α1β2γ2S receptors (see Table 3, and Fig. 28 A). At concentrations ≥ 
30 µM Actein elicited small currents in the absence of GABA. This direct activation did, 
however, not exceed 2% of the maximal GABA-induced current (n=7) (data not shown). 
Representative traces for direct activation of GABAA receptors are illustrated in insets in Figs. 
28 B and 29 B). 
 
 
10.2.3 α-SUBUNIT DEPENDENCE OF IGABA MODULATION BY ACTEIN 
In order to investigate a possible α-subunit specificity of actein action, the α1 subunit was 
substituted by α2, α3, α4, α5 and α6, respectively. Different α subunits were expressed in 
combination with a β2 subunit to analyse the modulation of IGABA (in the case, α4 and α6 
containing receptors additionally a γ2S subunit was co-expressed) (Fig. 27 A, Table 3). The 
highest efficiency was observed for receptors containing either α2 or α3 subunits, revealing a 
maximal potentiation of IGABA (EC5-10) of 1677.6±225.3% (n=8) and 1322.5±237.8% (n= 8), 
respectively, followed by α1-containing receptors (n=8). 
Actein displayed a considerably lower efficiency on GABAA receptors composed of α4 and 
α6 subunits (811.6±96.6%; n=5 and 840.2±117.0%; n= 6, see also Table 3). The effect of 
actein was least pronounced on GABAA receptors containing α5 subunits with an IGABA 
enhancement of 225.8±44.8% (n=7).  Comparison of the potencies of the respective subtypes 
revealed only minor differences, with potencies ranging from 29.5±12.9 µM (α1β2γ2S) to 












Number (n) of 
experiments 
α1β1 56.2 ±12.8 2169.4±374.5 1.8±0.3 15 
α1β2 50.0±10.9 1466.7±220.7 1.6±0.3 9 
α1β3 44.5±18.2 2027.0±398.9 1.2±0.1 8 
α1β2γ2S 29.5±12.9 1091.2±124.6 1.1±0.1 8 
α2β2 38.3±11.6 1677.6±225.3 1.6±0.3 8 
α3β2 50.8±9.3 1322.5±237.8 1.8±0.2 8 
α4β2γ2S 63.5±20.0 811.6±94.6 1.2±0.2 5 
α5β2 43.6±22.5 225.8±44.8 1.2±0.4 7 
α6β2γ2S 33.4±15.9 840.2±117.0 1.1±0.4 6 
 















































Figure 28 Modulation of IGABA through GABAA receptors containing different α-subunits 
(A) Concentration-effect curves for the action of actein on α1β2γ2S ( ), α2β2 (▲), α3β2 ( ), α4β2γ2S 
(◄), α5β2 (■), α6β2γ2S ( ) receptors using an EC5-10 GABA concentration (EC50 and Hill-coefficient 
values are given in Table 3). Data points represent means ± S.E. from at least 4 oocytes from ≥ 2 
batches. (B) Typical IGABA recordings illustrating concentration-dependent modulation by actein of 
GABA elicited chloride currents through α2β2-containing receptors. Direct activation of GABAA 






10.2.4 INFLUENCE OF DIFFERENT β-SUBUNITS ON IGABA     
                       POTENTIATION BY ACTEIN 
In order to determine the contribution of the β subunits on the effect of actein on GABAA 
receptors, the modulation of the respective subtypes (α1β1 and α1β3, respectively) was 
analysed. A comparison of the concentration-effect curves for actein on GABAA comprising 
either β1 or β3 receptors reveals a very similar modulation of GABAA receptors in regard to 
























Figure 29 Influence of the β-subunit incorporated in the receptor on IGABA modulation by actein 
(A) Concentration-effect curves for the action of actein on α1β1  (■)-, α1β2 (▲)- and α1β3 (●)-receptors 
using an EC5-10 GABA concentration (EC50 and Hill-coefficient values are given in Table 3). Data 
points represent means ± S.E. from at least 4 oocytes from ≥ 2 batches.  
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(B) Typical IGABA recordings illustrating concentration-dependent modulation by actein of GABA 
elicited chloride currents through α1β1 receptors. Direct activation of GABAA receptors during 
preincubation with 300 µM actein is shown in an inset. 
 
      10.2.5 MODULATION OF IGABA BY ACTEIN AT DIFFERENT GABA  
CONCENTRATIONS 
In order to gain further insight into the mechanism of IGABA modulation by actein, GABA 
concentration-response curves in the presence and absence of actein on α1β3 channels were 
compared (n=6). Actein was applied at a saturating concentration of 300 µM. At this 
concentration, actein shifted the concentration-effect curve towards lower GABA 

















Figure 30  (A) GABA concentration-effect curve of α1β3 GABAA receptors (control, ■) and in the 
presence of 300 µM actein (●).Corresponding EC50-values and Hill-coefficients were 3.1±0.5 µM and 
nH= 1.4 ±0.2 (control) and 1.5 µM ±0.3 µM and nH =1.4 ± 0.1 (Actein), respectively.  
(B) Representative traces illustrating GABA-induced chloride currents through α1β3 receptors in the 





10.2.6 PERFORMANCE IN THE OPEN FIELD TEST (OF) AFTER ACTEIN  
           ADMINISTRATION 
 To determine explorative behaviour actein-treated (n=8 for all concentrations) and control 
(n=11) mice were studied by means of the open field test. As shown in Figure 31 A, B and C, 
actein at concentrations ≥2 mg/kg per kg bodyweight (KG) significantly decreased 
ambulation in all areas of the open field as well as the overall ambulation compared to control 
animals, at concentrations ≥20 mg/kg mice covered a more than 50% reduced distance 
(2.88±0.24m control vs. 1.35±0.16m 20 mg/kg KG actein). 0.6 mg/kg KG actein slightly 
increased the distance travelled in the centre region. This increase was, however, not 
significant. Actein (≥ 6 mg/kg) significantly (p<0.05) decreased the time spent in all areas 




















Figure 31 Ambulation and explorative behaviour in the Open Field Test was assessed over 10 min for 
control and actein-treated mice at the indicated concentrations (concentrations represent mg/kg KG). 
Bars indicate in (A) the total distance travelled, in (B) the distance travelled in centre in % of the total 
distance, in (C) the distance travelled in the centre and the intermediate region, in (D) the entries into 
the centre, in (E) the time spent in the centre in % of total time and in (F) the time spent in both the 
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centre and intermediate zone in % of the total time. (**) indicates statistically significant (p<0.05) 
differences. 
 
10.2.7 PERFORMANCE IN THE ELEVATED PLUS MAZE (EPM) AND  
                       LIGHT-DARK CHOICE TEST (LDT) AFTER ACTEIN     
                       ADMINISTRATION 
Actein significantly reduced motor activity at concentrations ≥6 mg/kg bodyweight in the 
open field test compared to vehicle (see Fig. 31). Thus, to assess a possible anxiolytic-like 
activity of actein, control mice (n=8) and their littermates treated with 0.2 (n=8) and 0.6mg/kg 
KG (n=8) actein were tested in the EPM. As illustrated in Fig. 32 A and B, actein at 0.2 mg 
/kg and 0.6 mg/kg increased the number of entries into the open arms and concurrenlty the 






























Figure 32 Behaviour in the Elevated Plus Maze Test was assessed over 5 min for control and actein-
treated mice at the indicated concentrations (concentrations represent mg/kg KG). Bars indicate in (A) 
the number of open arm entries, in (B) the number of open arm entries in % of total entries, in (C) the 
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time spent on the open arm, in (D) the time spent on the open arm in % of the total time, in (E) the 
number of closed arm entries and in (F) the number of closed arm entries in % of the total entries.  
 
 
 The number of closed arm entries did not differ significantly between the groups, suggesting 
unaffected motor activity (see Fig. 32 E and F).  
The anxiolytic effect of actein was less pronounced in the LDT. However, 0.2 mg/kg KG 
actein significantly increased the time spent in the lit area (Control 70.0 ± 2.5 %; n=8 vs. 0.2 
mg/kg KG actein 77.1 ± 3.0%) (p< 0.05). Neither significant changes in distance travelled 
(Fig. 33 B) nor number of entries (Fig. 33 C) were observed for control and actein-treated 


















Figure 33 Behaviour in the Light-Dark Choice Test was assessed over 10 min for control and actein-
treated mice at the indicated concentrations (concentrations represent mg/kg KG). Bars indicate in (A) 
the time in the lit area in % of the total time, in (B) the distance travelled in the lit area and in (C) the 
number entries from the dark compartment into the lit area within the first 5 min.  














10.2.8 EFFECT OF ACTEIN ON STRESS-INDUCED-HYPERTHERMIA   
           (SIH) 
The basal body temperature (T1) did not differ between control mice (36.8±0.2°; n=21) and 
actein-treated mice at the concentratons 2 mg/kg KG (37.0±0.2°; n=9), 6 mg/kg KG (36.8 
±0.1°, n= 10) or 20 mg/kg KG (36.8 ±0.1°; n=9).  
6 mg/kg KG (∆T = 0.6 ±0.1°) and 20 mg/kg KG actein (∆T = 0.4 ±0.1°), respectively, caused 





















Figure 34 Effect of actein on stress-induced hyperthermia. Bars indicate reduction of temperature 




     10.2.9 HOME CAGE ACTIVITY MEASURED AFTER ACTEIN  
                 ADMINISTRATION 
Basal activity and circadian rhythm of control and actein-treated mice were monitored in their 
home cages. Control and 2 mg/kg KG actein did not significantly differ; 6mg/kg KG actein 
caused a significant reduction of activity (illustrated in arbitrary mobility counts, see Fig. 35).  
The strongest effect was observed for 20 mg/kg KG nearly abolishing any activity. The effect 
reached a maximum after approximately 3 hours and lasted overall 12 hours.  




















Figure 35 Effect of actein on activity in the home cage over a time period of 24 h. Black line 
represents the saline group=control, green line 2 mg/kg KG actein, blue line 6 mg/kg KG actein and 
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      11. DISCUSSION 
The modulation of GABA-indcued chloride currents through GABAA receptors comprising 
α1, β2 and γ2S subunits by Valerian extracts at a concentration of 100 µg/ml was analysed by 
means the two-microelectrode voltage clamp technique (see Fig. 18; see also Trauner et al., 
2008). As shown in Fig. 18, the extracts revealed a significant stimulation of IGABA. A major 
role of VA in IGABA modulation was established in experiments, where this compound was 
applied at different concentrations (see Fig. 19 B, C and D) to GABAA receptors expressed in 
Xenopus oocytes.  
 
      11.1.1 SUBUNIT SPECIFICITY OF IGABA STIMULATION BY VALERENIC  
                        ACID 
In order to obtain insight into the molecular basis of the VA action, the modulation of 
GABAA channels composed of different α, β and γ subunits was analysed. As illustrated in 
Fig. 19, coexpression of γ2S reveals a trend towards enhanced IGABA stimulation (Figs. 19 B 
and C). This effect was, however, only significant for α2β2γ2S receptors (Table 2). Omitting 
the γ1 subunit did not significantly affect stimulation of either α1β2 or α2β2 receptors (Tables 1 
and 2). The stimulatory action of VA was not significantly affected by coexpression of α2, α3 
or α5 instead of α1. A lower efficiency of VA was observed for α4 incorporating receptors 
(α4β2γ2S) (maximal enhancement of IGABA 68.9 ± 14.1%), significantly different from all of 
the subunit compositions investigated except α3β2 and α5β2. This finding might help to 
identify determinants of VA efficiency in future studies (Fig.19 D, Tables 1 and 2). 
In contrast, variation of the β subunits strongly influenced the effect on IGABA stimulation by 
VA (Fig. 22). The highest efficiency was observed for α1β3 followed by α1β2 channels (Table 
1). Replacing β2 by β1 almost completely abolished the stimulatory effect of VA. These data 
suggest a preferential action of VA on receptors containing β2 or β3 subunits. This finding 
was confirmed by the lack of VA action on α1β2N265S channels. Point mutation N265S in β2 
abolished the modulatory action of VA (Fig. 22). Replacing the serine in the β1 subunit 
(β1S290) by the corresponding asparagine of β2 induced VA sensitivity. This finding suggests 
that IGABA modulation may be mediated by VA interaction with the lorecelzole site, or 
alternatively, reflects an effect of β2N265S on the transduction pathway of VA action. Similar 
β-subunit specificity of loreclezole action displaying strong stimulation of receptors 
containing either a β2 or a β3 subunit support this notion (Wingrove et al. 1994).  
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An interaction of VA with N289 at the carboxyl terminal end of the pore-forming M2 
transmembrane domain could explain enhancement of IGABA by lower VA concentrations (e.g. 
by a destabilizing the closed channel conformation) and an apparent "open channel" inhibition 
at higher concentrations (Khom et al., 2007).  
 
11.1.2 SLOW ACTIVATION AND DEACTIVATION OF IVA  
At high concentrations, VA directly activated GABAA receptors. A direct activation of 
GABAA receptors was reported for a number of modulators including pentobarbital, 
etomidate, propofol or loreclezole (Schulz and Macdonald, 1981; Feng et al. 2004; Lam and 
Reynolds, 1998; Sanna et al., 1996; Hong and Wang, 2005). This VA induced current was 
relatively small and comparable for α1β3 (6.2 ± 2.0%) and α1β2 (10.7 ± 1.5%, stimulation of 
maximal IGABA) receptors.  
IVA developed much slower than IGABA and IVA was non-desensitizing (Fig. 23). Furthermore, 
the current deactivation time constants (τdeact.) were much slower in IVA compared to IGABA 
(τdeact(VA, 30-300 µM)= 2083 ± 232 ms, n=5). The time of IVA deactivation thus significantly 
exceeds the characteristic time of solution exchange whereas the time required for washout of 
1 µM GABA (τdeact = 200 ± 10 ms, n=7) corresponds to the time of solution exchange 
(Baburin et al., 2006). Such a slow deactivation usually accompanies enhanced 
desensitization (e.g. Jones and Westbrook, 1995; Haas and Macdonald, 1999). This was 
obviously not the case for IVA (Fig. 23 A). The mechanism underlying slower kinetics of IVA 
is currently not clear and warrants future studies. Direct activation of GABAA channels by 
VA may, however, also be explained by an interaction of VA with the GABA binding site as 
IVA were efficiently inhibited by bicuculline (1 µM). However, it cannot be excluded that 
conformational changes induced by bicuculline indirectly affect VA action (see also Ueno et 
al., 1997).  
These data show that VA is an agonist with much lower efficiency than GABA. The maximal 
current induced by the highest VA concentration of 300 µM (higher concentrations were not 
testable due to limited solubility) did not exceed 15% of the current induced by saturating (1 
mM) GABA concentrations (Khom et al., 2007).  
 
       
11.1.3 EVIDENCE FOR OPEN CHANNEL BLOCK 
At high concentrations (≥30 µM) a “wash-off” current occurred upon washout of VA. A 
straightforward interpretation of this finding is that VA rapidly unbinds from its binding site 
within the open channel (see also Rho et al., 1996; Dalziel et al., 1999; Akk and Steinbach, 
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2000; Krampfl et al., 2002; Feng et al., 2004). Such a scenario is supported by the 
concentration-dependent increase of this current suggesting a concentration-dependent open 
channel block (Fig. 23). Further evidence for an open-channel block mechanism comes from 
the accelerated IGABA decay in the presence of high concentrations of the structurally related 
acetoxy-VA (Fig 24 B). In order to further explore this possibility, the bell-shaped 
concentration-response curve that was typically seen for VA action was simulated. The 
corresponding IC50 (~190 µM) value that was estimated assuming that the accelerated IGABA 
decay reflects open-channel block (Fig. 24 C) nicely agrees with the simulation of the bell-
shaped concentration-response curve assuming a low affinity open-channel block mechanism 
for VA (simulated IC50 = 190 µM). 
These findings suggest that VA and acetoxy-VA might act at the same site in the channel 
pore. The discussed open channel block mechanism remains however, hypothetical, because 
acetoxy-VA may also interact with a different binding site than VA. 
Surprisingly, an enhanced IGABA decay was observed only for acetoxy-VA and not for the 
structurally related hydroxy-VA. This finding suggests that substitution of the hydrogen in 
position 1 of the hexahydro-indene ring by a hydroxyl- or acetoxy-group defines not only the 
modulatory action but also the affinity for open GABAA channels.  
The complex mechanism of VA action (including modulation of IGABA, direct activation of 
GABAA channels and open channel block) complicates a straightforward estimation of the 
efficiencies and potencies of VA for the different subunit compositions. This is illustrated in 
Figs 19 B-D and 22 where the modulatory action is apparently superimposed by inhibitory 
action.  
Taken together a subunit specific modulation of GABAA receptors by VA (β3 > β2 >> β1-
containing receptors, Fig. 22) was described. Positive allosteric modulation is caused by a 
VA-induced increase in the GABA sensitivity (Fig. 20). The threshold concentration (1 µM) 
of this modulatory action is in the range of the estimated plasma concentration of VA 
(Anderson et al., 2005). At high concentrations, VA activates GABAA channels directly (Fig. 
23) and also blocks the channel. The clinical evidence for Valerian effects is, however, still 
controversial (see Sampson, 2005 and De Smet, 2002 for review). However, these data open 
the perspective that the proposed sedative, hypnotic and anxiolytic effects suggested for 





11.2 MODULATION OF GABAA RECEPTORS BY ACTAEA RACEMOSA  
        EXTRACTS 
Preparations made from the rhizome of Actaea racemosa are widely marked as herbal 
remedies for the treatment of menopausal symptoms. US sales figures in 2005 reached $9.7 
million. The clinical efficacy of these extracts is still unclear (for review, see Borrelli and 
Ernst, 2008) and the precise mechanism of action is currently unknown. It was hypothesized 
that Actaea racemosa ingredients compete with estrogen for binding sites and exerts a 
positive estrogenic effect. Other data were interpreted that it may act as a selective estrogen 
receptor modulators, depending on the tissue receptors (Bodinet and Freudenstein, 2004), and 
that it may also exert an agonistic effect on serotonin receptors (Burdette et al., 2003). In 
addition, Actaea racemosa extracts may decrease luteinizing hormone levels, leading to a 
decrease in hot flashes (Borrelli and Ernst, 2002; Carroll, 2006). Vermes et al. (2005) reported 
a significant reduction of insomnia- and anxiety-related disorders in menopause by an 
isopropanol extract (Remifenin®) of Actaea racemosa containing the triterpene glycoside 
actein. 
The modulation of IGABA by 3 different Actaea racemosa extracts (kindly provided by 
Univ.Prof. DDr. Brigitte Kopp and colleagues Mag. Gabriele Trauner and Mag. Ulrike Jäger) 
was examined by means of the two-microelectrode voltage clamp techniqu (see Fig. 27). All 
the tested extracts exhibited a positive modulatory effect.  
 
11.2.1 ACTEIN MODULATION OF GABAA RECEPTORS COMPOSED OF   
          DIFFERENT α OR β SUBUNIT VARIANTS 
Actein was identified as an efficient modulator of GABAA receptors (see Figs. 28 and 29).  
The modulation of heterologously in Xenopus oocytes expressed GABAA receptors 
comprising different subunit combinations (see Table 3) by actein was studied, as illustrated 
in Figs. 28 and 29, half-maximal stimulation of IGABA occurred at concentrations ≥30 µM. 
Maximal IGABA enhancement occurred at 300 µM of actein (see Figures 28 A and 29 A, see 
also Table 3). At concentrations ≥30 µM actein directly activated GABAA receptors (i.e. in 
the absence of GABA). In order to obtain insight into the underlying molecular basis, the 
modulation of GABAA channels composed of different α, β and γ subunits was investigated. 
As illustrated in Figs. 28 A and 29 A, actein modulated all tested receptor subtypes, 
irrespective of the subunit composition. However, different efficiencies were observed for 
different receptor subtypes (see Figs., 28 A and 29 B, Table 3). 
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Most pronounced modulation of IGABA occurred at α1β1 receptors, whereas only a weak 
stimulation was observed in α5β2. The order of IGABA stimulation was 
α1β1>α1β3>α2β2>α1β2>α3β2>α1β2γ2S>α6β2γ2S>α4β2γ2S>>α5β2 (see Figs., 28 A and 29 A, 
Table 3).  
 
      11.2.2 ACTEIN MODULATES IGABA INDEPENDENT ON THE GABA  
                        CONCENTRATION 
Actein (300 µM) modulated IGABA induced by different GABA concentrations to a 
comparable extent. The GABA concentration-effect curve in the presence of 300 µM actein 
was shifted towards higher GABA sensitivity and Imax-GABA was increased (see Fig. 30 A). At 
concentrations ≥30 µM actein directly gated GABAA receptors irrespective of the subunit 
composition, however the currents induced by actein did not exceed 2% of Imax-GABA. Similar 
pharmacological features have been previously reported for other allosteric modulators such 
as barbiturates (Schulz and Macdonald, 1981; Thompson et al. 1996; Feng et al. 2004), 
anaesthetics such as etomidate (Hong and Wang, 2005) or neurosteroids such as THDOC 
(Lambert et al., 2003; Hosie et al., 2006). 
 
11.2.3 IN VIVO EFFECTS OF ACTEIN 
Open field test 
A decrease in locomotor activity in the OF test represents a reliable measure for sedative-like 
effects in murines (Cheng et al. 2006). Actein significantly decreased the distance travelled by 
mice in the OF test compared to their vehicle-treated littermates (see Fig. 31). At 6 mg/kg KG 
and 20 mg/kg KG actein, respectively, animals covered half of the distance compared to the 
control group suggesting a sedative effect. Interestingly, 0.6 mg/kg KG actein induced a slight 
increase in the distance travelled in the centre as well as in the time spent in the centre. This 
increase, which may indicate an anxiolytic action of actein, however, was not significant.    
Concentrations higher than 60 mg/kg did not further decrease the locomotor activity. 
However, this effect is presumably not due to reaching saturation, but more likely due to the 
poor solubility of actein in the vehicle. Previously, it has been suggested that α1 containing 
receptors mainly contribute to the sedative effects of ligands of the benzodiazepine 
recognition site (Rudolph et al., 1999; Low et al., 2000; Crestani et al., 2001). This is in 
agreement with the results of the electrophysiological experiments in the Xenopus assay, 
showing a strong effect of actein on GABAA receptors containing α1-subunits (see Fig. 28 A 
and 29 A, see also Table 3). 
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Elevated Plus Maze and Light- Dark Choice Test  
A trend towards an anxiolytic effect of actein was observed in the OF test. In the EPM test, 
actein caused an increase of the time spent in the open arms including visits of open arms (see 
Fig. 30). This behaviour is commonly associated with an anxiolytic activity of the tested 
compound (Crawley, 2008). However, this effect was not significant and at higher 
concentrations (≥2 mg/kg) actein even reduced a significant decrease in the time spent in the 
open arms of the elevated-plus-maze (data not shown). Nonetheless, this apparent loss of 
anxiolytic-like activity was presumably due to a developing sedative-like effect. In the LDT 
test, actein significantly increased the time spent in the brightly lit arena, thus suggesting a 
retained anxiolytic effect (Fig. 31). 
 
Stress-induced hyperthermia 
Assessment of anxiolytic-like activity in the EPM and the LDT is highly dependent on an 
intact locomotor activity (Crawley, 2008). Actein revealed in the OF, EPM and LDT a trend 
towards anxiolytic activity, however the observed increases (see Figs. 30 and 31) were not 
significant compared to control (except in the LDT). In the SIH, 6 and 20 mg/kg actein caused 
a significant decrease of ∆T, supporting the idea that the anxiolytic effect is concurrently 
superimposed by the sedative activity. My data indicate that actein efficiently modulates 
GABAA channels composed of α2β2 and α3β2 subunits (see Fig. 228, Table 3). This is in line 
with data of Low et al. (2000), McKernan et al. (2000), Collins et al. (2002), Dias et al. (2005) 
and Atack et al. (2006) illustrating that GABAA receptors comprising either α2 or α3 
apparently mediate the anxiolytic effects of ligands of the benzodiazepine binding site. Taken 
toghether these data support the idea of an anxiolytic potential of actein. 
 
Home Cage Activity 
In order to gain insight into the time of course of action, animals treated with actein were 
monitored for 24 hours. 3 hours after injection, the actein activity reached a maximum nearly 
completely abolishing any activity. After 12 hours neither control group nor actein-treated 
group showed any differences in their behaviour, suggesting that actein in contrast to the 
frequently prescribed benzodiazepines could induce less hang-over effect or daytime sedation 






Taken together, actein was identified as a highly efficient modulator of GABAA receptors. In- 
vivo, actein was shown to induce sedation and concurrent anxiolysis. These data suggest that 
Actaea racemosa effects in menopause (Vermes et al., 2005; Cheema et al., 2008) may at 
least be partially explained by an allosteric modulation of GABAA receptors. Other 




Valerian and Actaea racemosa extracts are commonly used as “herbal medicinal products”, 
while their mechanisms of action are largely unknown. In this study, I have demonstrated that 
Valerian and Actaea racemosa extracts at a concentration of 100 µg/ml enhance chloride 
currents through GABAA receptors (IGABA).  
Valerenic acid (VA) selectively enhances IGABA through receptors incorporating β2 or β3 
subunits and its effect is not γ-subunit dependent. The stimulatory effect of VA on α1β2 
receptors was substantially reduced by the point mutation β2N265S (known to inhibit 
loreclezole action). VA displayed a significantly lower efficiency on channels incorporating 
α4 subunits (α4β2γ2S receptors). At high concentrations (≥ 100 µM) VA and acetoxy-VA 
inhibit IGABA suggesting an open-channel block. In summary, VA was identified as a subunit-
specific allosteric modulator of GABAA receptors that is likely to interact with the loreclezole 
binding pocket. 
Actein (a compound isolated from Actaea racemosa) was identified as an efficient modulator 
of GABAA receptors displaying the strongest effect on α1β1 receptors (2169.4±374.5%), 
whereas on α5β2 containing receptors a substantially weaker efficiency was observed 
(225.8±44.8%). Actein (6 mg/kg) significantly decreased the spontaneous motor activity of 
mice in the open field test. A significant decrease of ∆T (difference of basal temperature 
before and after actein injection; 6 and 20 mg/kg actein) was observed in the stress-induced 
hyperthermia test. These in vivo data suggest that sedative and anxiolytic properties of actein 
may contributes to the treatment of postmenopausal disorders with Actaea racemosa extracts. 
90 
13. ZUSAMMENFASSUNG 
Extrakte von Baldrian (Valeriana officinalis) und Traubensilberkerze (Actaea racemosa) 
finden Anwendung als „Phytopharmaka“. Ihre Wirkmechanismen sind unbekannt. In der 
vorliegenden Arbeit konnte gezeigt werden, dass sowohl Baldrian- als auch 
Traubersilberkerzen-Extrakte eine deutliche Stimulation von Chloridströmen (IGABA) durch 
GABA Rezeptoren induzierten.  
Valerensäure (VA), ein wichtiger Inhaltsstoff des Baldrians, wurde als Untereinheiten-
spezifischer Modulator von GABAA Rezeptoren identifiziert, da ausschließlich β2/3 
Untereinheiten inkorporierende Rezeptoren positiv moduliert wurden. Das Einführen der 
Punktmutation β2N265S (welche die Modulation von GABAA Rezeptoren durch Loreclezol 
hemmt) reduzierte die Modulation der Rezeptoren durch VA. VA zeigte außerdem eine 
geringere Effizienz an α4β2γ2S GABAA Kanälen. In höheren Konzentrationen (≥100 µM) 
blockierten VA und Acetoxy-VA IGABA über einen “open-channel-block” Mechanismus. 
Zusammengefasst wurde VA als Untereinheiten-spezifischer Modulator von GABAA 
Rezeptoren identifiziert, der möglicherweise mit der Loreclezol-Bindungsstelle interagiert.  
Actein, ein Inhaltsstoff der Traubensilberkerze, wurde als effizienter Modulator von GABAA 
Rezeptoren identifiziert, wobei die stärkste Potenzierung von IGABA an α1β1 Rezeptoren 
beobachtet (2169.4±374.5%) wurde, während der Effekt an α5β2 Rezeptoren deutlich 
schwächer ausgeprägt war (225.8±44.8%).  
Actein (6 mg/kg) reduzierte signifikant die spontane Motoraktivität der Mäuse im Open Field 
Test. Im Light/Dark Choice Test, verbrachten Actein-behandelte Mäuse im Vergleich mit 
Kontrolltieren signfikant mehr Zeit im hellbeleuchten Teil der Box. Eine deutliche Reduktion 
von ∆T (Differenz der Körpertemperatur vor und nach Actein-Injektion; 6 and 20 mg/kg 
Actein) wurde im Stress-induced Hyperthermia Test beobachtet. Diese Daten legen nahe, dass 
Actein in vivo über eine Interaktion mit GABAA Rezeptoren sedative und anxiolytische 
Wirkungen induzieren kann und dass diese Effekte möglicherweise zur beobachteten 
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Sprachkenntnisse 
Deutsch: Muttersprache 
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Italienisch: gut 
